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ABSTRACT 
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and 
PILOT SCALE PROCESS DEVELOPMENT AND cGMP PRODUCTION OF CANCER 
TESTIS ANTIGEN MELAN-A 
Cameron Lee Bardliving, Ph.D. 
Cornell University 2013 
 
Detection or delivery of a diverse range of biomolecules in field portable devices is an important 
area of research in the fields of environmental pollution, homeland security, and medicine.  The 
demand for hand-held and low cost detection in these fields has led to the development of novel 
analytical systems such as Surface Enhanced Raman Spectroscopy (SERS) and Molecularly 
Imprinted Polymers (MIP). SERS is rapidly emerging as a tool for biological assays, chemical 
sensing, and electrochemistry. Whereas, Molecularly Imprinted Polymers have been developed 
as systems for solid phase extraction, chemical separation, and controlled release. In this 
dissertation, several systems were developed using nanotechnology and polymer synthesis to 
develop chemical sensors and a drug delivery system. A substrate for pesticide detection was 
developed by conjugating oligonucleotides specific for the pesticide malathion to the surface of a 
SERS substrate that detected the organophosphorus pesticide malathion down to the micromolar 
level. A SERS substrate was also developed by grafting a molecularly imprinted polymer of 
methacrylic acid and ethylene glycol dimethacrylate to surface of a gold coated silica 
microparticle that was able to capture and detect the pesticide thiabendazole. Molecularly 
 iii 
 
imprinted polymers were investigated as a drug delivery system for the chemotherapeutic 
doxorubicin which showed strong imprinting and temperature sensitive controlled release of 
drug. Lastly, a cGMP pilot scale process was developed to produce gram levels of the cancer 
vaccine Melan-A for phase I clinical trials.     
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Chapter 1: Introduction 
 
CANCER IMMUNOTHERAPY 
The pharmacodynamic effect of immunotherapeutics is defined by various modulations of 
patient anticancer immune responses to selectively eliminate cancerous tissue. 
Immunotherapeutics are generally divided into two catergories; passive or active
1-3
. Passive 
immunization involves the introduction of exogenous immune system components into the body 
to cause a cytotoxic effect. Active immunization rather stimulates the body’s own immune 
system to combat an infection or chronic disease. For over two centuries, active immunization 
has been at the forefront of immunotherapeutics beginning with the work of Edward Jenner in 
developing the first smallpox vaccine from cowpox lesions
3
. Since that time, preventative and 
therapeutic vaccines for poliomyelitis, typhoid, cholera, diphtheria, and hepatitis B among others 
have been developed and in some cases used to eradicate the disease
3
. The idea for the 
development of active immunotherapeutics to combat cancer was first proposed in the 1890s by 
Paul Ehrlich and William Coley and the first reported successful implementation was by Ronald 
Levy and colleagues for B-cell lymphomas in 1982 
4
.  
Cancer immunotherapeutics are presently a main component for cancer treatment regimens. 
Modern cancer immunotherapeutics include prophylactic vaccines, monoclonal antibodies, 
systemically administered cytokines for activation of cell signaling cascades, and local delivery 
of immunotoxins/adjuvants to illicit immune response (Table 1.1). All of these strategies take 
advantage of the immune system’s ability to recognize not only foreign antigens but also 
abnormal expression of proteins by tumors. Cancer immunotherapies generally need to overcome 
 2 
 
several biological hurdles during development including identification of appropriate targets, 
adequate activation of the immune system, suppression of cytotoxic pathways, and proper 
interaction with immune system components
2
. Additionally  patient heterogeneity
5
 and lack of 
information on the proper dosing schedule for many cancer immunotherapeutics when compared 
to the measurable pharmacokinetic and pharmacodynamic effects of classic chemotherapy 
drugs
2, 5
 is a deterrent for implementation of immunotherapies. Cancer immunotherapeutics, in 
particular cancer vaccines, also often lack measurable biomarkers to determine the maximal 
tolerated and maximal effective dose of the therapy and may have insufficient volumetric 
response in the tumor in comparison to the effects of cytotoxic drugs
2, 6
. Therefore the current 
method for clinical assessment of tumor therapies is not necessarily transferable to cancer 
vaccine assessment. Future work will involve coordination between government, industry, and 
academia to institute broader definitions for clinical trials design and analysis to incorporate the 
therapeutic benefits of cancer vaccines 
7
. The chapter will focus on two of immunotherapies; 
monoclonal antibodies and recombinant vaccines.   
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Table 1.1 Approved Cancer Immunotherapies
1, 7
. Adapted from Dougan et al., and Huang et al.   
Therapy Indication Host 
Antibody   
Rituximab Non-Hodgkin’s lymphoma, 
Chronic lymphocytic leukemia 
Chinese Hamster Ovary 
(CHO) 
Ibritumomab tiuxetan Non-Hodgkin’s lymphoma CHO 
Tositumomab Non-Hodgkin’s lymphoma Mammalian 
Alemtuzumab Chronic lymphocytic leukemia CHO 
Gemtuzumab Acute myelogenous leukemia NS0 (murine myeloma) 
Trastuzumab Breast cancer CHO 
Cetuximab Colorectal cancer SP2/0 (murine myeloma) 
Natalizumab Multiple sclerosis (MS) CHO 
Tremelimumab Metastatic melanoma  
Panitumumab Colorectal cancer CHO 
Bevacizumab Colorectal cancer, Lung cancer CHO 
Cytokine   
IFN-α Melanoma, Renal cell carcinoma E. coli, CHO 
IL-2 Melanoma, Renal cell carcinoma E. coli 
TNF- α Soft tissue sarcoma, Melanoma   
Peptide Vaccines   
Hepatitis B Virus (HBV) Hepatocellular carcinoma S. cerevisiae 
Human papillomavirus (HPV) Cervical cancer S. cerevisiae 
Recombinant Therapeutic 
Vaccines 
  
MAGE-A3 Non-small cell lung cancer 
(NSCLC) and Melanoma 
E. coli 
NY-ESO-1 Various malignancies  E. coli 
Melan-A Melanoma E. coli 
SSX2 Synovial sarcoma  E. coli 
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Monoclonal Antibodies 
One of the most successful forms of cancer immune therapy is monoclonal antibodies (mAb) 
treatment
8
. Antibodies, also known as immunoglobulins, consist of two copies of two 
polypeptide chains which recognize target antigen epitopes and play an essential role in 
protection from microorganisms. The development of the hybridoma technique for monoclonal 
antibody production in 1975 by Kohler and Milstein 
9
, made it possible to engineer antibodies for 
treatment of chronic disease. In a little over a decade, a murine based mAb therapy, muromonab 
targeting CD3 in patients with renal transplants, was approved by the FDA
10
.  Yet murine 
derived antibodies were found to have several drawbacks which prohibited their clinical 
effectiveness. One issue is that animal derived products cause an immune response in the patient 
which limits its dosage schedule. Additionally, murine mAb generally have short half-lives in 
vivo, and do not elicit antibody-dependent cellular cytotoxicity (ADCC) due to insufficient 
binding to human compliment
1, 3, 7
.   To overcome these limitations new monoclonal antibody 
therapeutics were introduced that were chimeric, humanized, or full human antibodies. Chimeric 
antibodies are fusion protein constructs most often consisting of a substituted Fc region.  
Basliximab (simulect) a chimeric antibody toward CD25 (IL-2Rα) to block binding with IL-2 
was approved in 1998 
3
. Research continued into reducing the mouse component of the antibody 
down to 5-10% which resulted in reduced immunogenicity, improved serum half -life, and 
cytotoxic effect
11
. Other chimeric or fused antibodies were later commercialized including 
infliximab (remicade) and etenercept (Enbrel) against the cytokine TNFα3. Humanized 
antibodies, where non-human antibody sequences are modified to have sequence identity with 
antibodies derived from humans, were developed to take advantage of recombinant expression of 
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of these constructs in mammalian cell culture systems
12
.  The first humanized monoclonal 
antibody (daclizumab, Zenapax) was approved by the FDA in 1997 targeting CD25 expressing 
lymphocytes to reduce transplant allograft rejection
2, 3
. These second generation antibodies also 
targeted cytokine receptors or were conjugated with radiolabels and toxins to improve 
cytotoxicity. Examples are rituximab which was conjugated with 
90
Y targeting CD20 for B-cell 
non-Hodgkin’s lymphoma13 
Monoclonal antibodies therapeutic effect can be characterized by three mechanisms of action: 
antibody-dependent cellular cytotoxicity (ADCC), compliment dependent cytotoxicity (CDC), 
and cell signaling interference
1, 8
. In ADCC, mAbs can bind to antigen presented on the tumor 
cell surface which serves as a target for the natural killer (NK) cells FcγRIII receptor. Cytolytic 
proteins are then released from the NK cells and the tumor cell is lysed. The cellular debris is 
taken up by antigen-presenting cells, which present the tumor antigens to B cells and leads to the 
release of tumor antibodies. Cytotoxic T lymphocytes (CTLs) recognize these antigens and 
attack the tumor and provide the patient with immunological memory
8
. Compliment dependent 
cytotoxicity is a part of the innate immune system where by a membrane attack complex is 
formed as the end product of antibody targeting a specific antigen on the tumor surface
8
.  As 
many of the tumor associated antigens (TAA) are growth factors (i.e. endothelial growth factor 
receptor) another mechanism of monoclonal antibody action is direct attenuation of a receptor or 
receptor dimerization leading to decreased proliferation
8
. The reduced growth rate of the tumor 
also allows for more effective use of chemotherapy agents as the tumor cells are more sensitive 
at more normal proliferation rates. The mAb trastuzumab (Herceptin) against HER2/neu and 
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endothelial growth factor receptor has been shown to improve survival in patients when used in 
combination with paclital or other chemotherapeutics
14-16
 
Monoclonal antibody immunotherapy is also generally not as toxic as conventional 
chemotherapy agents and can activate titer levels rapidly
1
. Over 25 different antibodies are 
currently in clinical use
17
. With improvements in industrial scale production systems
18
, serum 
half-life, and efficacy monoclonal antibodies will continue to expand the immunotherapeutic 
market that is growing at a rate of 14% per year as of 2007
19
. 
 
Figure 1.1 Antibody-dependent cell-mediated cytotoxicity. a) Monoclonal antibodies (MAbs) 
bind to target antigens on surface of tumor cell. b) Natural killer cells expressing the 
transmembrane isoform of CD16 engage antibodies on surface of tumor cell. c) Cross linking of 
FCγIIIa receptors stimulates release of cytokines and cytolytic granules. d) Interferons and 
granzymes enter cell triggering apoptosis.    
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Recombinant Immunotherapeutics/Vaccines 
Vaccines are biological preparations of killed, attenuated, subunit, or polysacchide conjugate of a 
pathogen used to improve immunity to a disease. While prophylactic or therapeutic vaccines to 
microbial or viral infectious diseases have been in development for over two centuries, vaccines 
for chronic illness such has cancer have not seen the same level of success. However, as 
numerous cancers are caused by microbial infections, traditional vaccination strategies can be 
used to treat these cancers. Highly conserved epitopes that are expressed by microbes can be 
used to develop effective vaccination strategies. The first available recombinant prophylactic 
vaccine for cancer therapy approved by the FDA (1986) was the vaccine for hepatitis B virus 
(HBV)
20
. Hepatitis B infects the liver leading to hepatitis. This chronic inflammation can 
eventually cause hepatocellular carcinoma in a subset of patients
21
. The vaccine contained a 
surface antigen that was administered in combination with an adjuvant to protect against all 
strains of HBV.  
The next breakthrough occurred with the development of the recombinant human papillomavirus 
(HPV) under the trade name Gardasil. HPV infections can lead to cervical cancer which results 
in 250,000 deaths per year worldwide and HPV 16 and 18 are associated with 70% of the 
cervical tumors
22
. Girls vaccinated with HPV 16 and 18 have a 98% prevention rate against 
cervical intraepithelial neoplasia and cervical cancer
22, 23
. The HPV vaccine is composed of four 
capsid proteins that can spontaneously assemble into virus-like particles (VLP) which are 
indistinguishable from native virus
24
.    
Therapeutic cancer vaccines derived from whole cells, tumor associated antigens (TAA) and 
viral vectors, have been investigated for cancer treatment. TAA vaccines are of particular interest 
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because they are gene products that are overexpressed by tumor cells but have basal or no 
expression in normal cells
25
. Among the well documented TAAs Her-2, p53, and cancer testis 
(CT) antigens, CT antigens show the most promise as a therapeutic as their expression outside of 
tumors is often limited to germ cells and trophoblasts which are not recognized by cytotoxic T 
lymphocytes 
25, 26
. John Beard first noted the similarities in biological expression between 
trophoblasts and cancer (trophoblastic theory of cancer) which eventually lead to the discovery 
of CT antigens
26
.  The first CT antigen, MZ2-E, was discovered through autologous typing and 
DNA cloning from a melanoma patient with CTLs that recognized the tumor
27, 28
.  The gene 
encoding MZ2-E was named MAGE1 and soon after the CT antigens B melanoma antigen 
(BAGE) and G antigen 1 (GAGE1) were discovered. The later development of the SEREX 
technique (serological analysis of cDNA expression libraries), which combined serological 
analysis with antigen cloning technology
29, 30
, led to the discover of the SSX gene family
31
 and 
the potent NY-ESO-1 antigen
32
. Presently, there are 44 known CT antigen gene families which 
can be divided based on chromosomal mapping either on the X chromosome or non-X 
chromosome
26
. Table 1.2 lists some of the major CT antigens as well as their expression patterns 
in normal and cancerous tissue. The function of many of the CT antigens is not understood but 
expression has been linked to promoter demethylation
33
.  
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Table 1.2 Select cancer testis antigens gene expression in normal and cancerous tissues 
34
  
Antigen Normal Expression 
Pattern 
Cancerous Expression Pattern 
MAGE Testis and pancreas Melanoma, lung, brain, esophageal and stomach, 
bladder, breast, skeletal muscle 
NYESO-1 Testis, placenta, 
pancreas, liver 
Esophageal, melanoma, prostate, transitional cell 
bladder, breast, lung, medullary thyroid, squamous 
head and neck carcinoma, cervical carcinoma 
BAGE Testis Melanoma, bladder, lung 
GAGE Testis Melanoma, sarcomas, Non-small cell lung cancer, 
head and neck tumors, bladder 
XAGE1 Testis, placenta, 
pancreas, spleen, thymus, 
lung, skeletal muscle 
Bone, muscle, melanoma, Ewing’s sarcoma, breast, 
lung, prostate 
SSX Testis Skin, bladder, breast, head and neck, colon, lung 
 
The recombinant MAGE-A3 and NY-ESO-1 have been produced in E. coli and have been 
evaluated in clinical trials as vaccines 
35-40
.  The recombinant proteins are often preferred over 
peptide segments as the multiple epitopes on the recombinant protein can stimulate strong 
activity of CD4
+
 and CD8
+
 T cell populations. NY-ESO-1 has been found to be one of most 
immunogenic CT antigens with expression across a variety of cancers including bladder, lung, 
ovarian, hepatocellular, and melanoma
34
. In a clinical trial, patients that were given NY-ESO-1 
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in combination with the adjuvant  ISCOMatrix observed higher antibody titers, reduced negative 
pharmacodynamics and CD4+ and CD8+  T cells specific for a range of NY-ESO-1 epitopes 
41
.  
The differentiation antigen presented in this work, Melan-A, is also a member of the MAGE 
gene family 
42
. Melan-A has been screened as a peptide prophylactic vaccine in a murine model 
and has been shown to elicit CTL response and tumor growth suppression of up to 60%
43
. The 
preference of use of recombinant proteins over peptides in clinical trials, has led to the work 
described here for pilot scale production of cGMP grade Melan-A for clinical trials.  
SURFACE ENHANCED RAMAN SPECTROSCOPY 
Background and Mechanisms 
Raman spectroscopy is a branch of vibrational spectroscopy in which the transitions between 
vibrational states are studied when a molecule in-elastically scatters light
44
.  The Raman effect 
occurs from the very small fraction of incident photons (e.g., ~1 in every 10
7
 photons) that 
couple to distinct vibrational modes of the molecule, resulting in in-elastically scattered radiation 
with a change in frequency.  The energy difference between the inelastic scattered radiation and 
the incident light corresponds to the energy involved in changing the molecule’s vibrational 
state.  Plotting the intensity of this energy change verses the related frequency shift produces the 
Raman spectrum. The Raman effect was first reported by CV Raman in 1928 using pure liquids 
or gases
45
. The utility of Raman as an analytical technique was limited until the 1970s when it 
was observed that adsorption of molecules to a roughened metal surface greatly enhanced the 
Raman signal intensity
46-48
. This set of discoveries and later work by Liao and Howard
49, 50
, 
confirmed that noble metal surfaces with nanoscale features can enhance the Raman scattering 
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signal of molecules adsorbed on the surfaces. This phenomenon became known as Surface 
Enhanced Raman Scattering (SERS).   
After the initial reports on SERS, a debate as to the mechanism of the enhancement raged for 
several decades
51, 52
. Currently it is believed that there are two synergistic mechanisms that are 
contributing to the enhancement factors of 10
6 
or greater. One mechanism is electromagnetic 
which results from the excitation of the localized surface plasmon resonance (LSPR)
53
.  LSPR is 
the flow of free electrons that can occur on noble metal nanoscale features, metal tips, or 
roughened metal surfaces
54
. The electromagnetic mechanism can be characterized by the 
examples of a metal nanoparticle in an external electric field. Since the particles diameter is 
smaller than the wavelength of light, the resulting electric field can be thought of as uniform 
across the entire particle. The magnitude of the electron cloud around the particle is defined by 
the equation: 
     (
        
         
)        
 This equation becomes resonant as the denominator approaches zero (Ɛin = -2Ɛout). The 
resonance excitation of the surface plasmon is believed to increase the local field experienced by 
the molecule
51, 52
. The particle can then not only enhance the incident light but also the resulting 
Raman scattering field
51
. The electromagnetic mechanism is thought to contribute as much as 10
4
 
to the enhancement factor of SERS although higher enhancement factors of 10
10
 are theoretically 
possible
52, 55
.   
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The second contribution to SERS enhancement comes from the chemical enhancement where 
there is excitation of molecule electronic states that are in coordination with the noble metal 
surface. This mechanism was largely speculative but evidence for chemical enhancement could 
be seen in the drastically different SERS enhancements of two different molecules under the 
same conditions. A model proposed by Lombardi et al. suggests that the transfer of charge from 
the highest occupied molecular orbital (HOMO) to the lowest unoccupied molecular orbital 
(LUMO) of absorbed molecule to the metal or vice versa can occurs at half the energy of the 
difference in the two energy states
56
.  This mechanism is thought to contribute less to the 
enhancement factor of SERS (10
2
-10
3
)
52, 57
 and is highly dependent on the molecule of interest
57, 
58
.   
To measure the signals of molecules with SERS, the distance of the molecule to the surface of 
substrate is critical. Generally SERS enhancement decays with respect to distance at a rate of r
-10 
52
. Therefore SERS effect is limited to a range of molecules that can make close contact with the 
noble metal surface typically less than a few angstroms
52, 59.  Nevertheless, this “limitation” can 
often be used to one’s advantage in SERS-based analyses by tailoring the nanoparticle surface to 
have affinity for a given analyte; thus, given the insensitivity of standard Raman, analytes that 
are localized near the noble metal surface are the only detectable species in a given sample.  
SERS also has little interference from water which gives it great potential for use in chemical 
and biological sensing systems
52
.  
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Surface Enhanced Raman Substrates 
One of the most widely studied areas in SERS applications is the design and fabrication of 
reproducible substrates. Most SERS substrates rely on the principle that electromagnetic field 
“hot spots” can be created between the nanosized gaps of clustered of nanoparticles on surfaces60 
or in solution
61
. Toward this end, metal particle aggregation has been one of the most widely 
employed substrate fabrication techniues
62, 63
 and is considered essential for producing a SERS 
effect
64, 65
;  This technique is simple and cost effective as it usually involves the simple reduction 
of a solution of gold or silver salts
66, 67
. Particles of various shapes and sizes can be produced in 
this manner such as tetrahedral silver nanoparticles
68
, star shaped gold nanoparticles
69
, to flower 
shaped doped silver nanoparticles
70
 with varying degrees of shape anisotropy for SERS effect.  
Gold nanorods have been widely used as reliable and tunable SERS substrate. By altering the 
aspect ratio of rods one can adjust of the longitudinal plasmon over a range of wavelengths to 
absorb at the excitation of the Raman source. Guo et al. showed that overlap of the surface 
plasmon resonance with the excitation of the laser increases the SERS enhancement effect using 
cetyltrimethylammonium bromide (CTAB) coated gold nanorods
71
. The plasmon matching to the 
excitation source wavelength has been shown to result in at least a 10-100 fold increase in 
enhancement compared to unmatched nanorods
72
 Liao et al. developed gold nanorod arrays 
using anodic aluminum oxide (AAO) template assisted nanofabrication which showed that 
ordered gold nanorod arrays had SERS hot spots localized along the longitudinal end of the rods 
whereas NaOH etched and aggregated rods localized hot spots at the junctions between the polar 
ends of the rods
73
.  
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Recent efforts have focused on the production of more ordered SERS substrates for more batch 
to batch reproducibility. The ideal SERS substrate would have several characteristics including 
but not limited to homogenous signal across the entire substrate, large enhancement factor, and 
cost efficient straight forward preparation
74
. In order to obtain large arrays of metallic 
nanoparticles, different surface functionalization approaches have been taken to either bind metal 
nanoparticles to a surface using linker molecules or self-assembly. Self-assembled monolayers 
(SAMs) have been used to great effect to assemble gold and silver nanoparticles for analyte 
detection on surfaces modified with thiol, amine, or oxide groups
75-77
.  Fan et al. self-assembled 
silver nanoparticles onto glass slides functionalized with 3-mercaptopropyltrimethoxysilane 
(MPTMS) and achieved a substrate with relatively uniform distribution of SERS signal across 
the entire surface
75
. A novel concept of coating a material to be studied with a shell of gold 
nanoparticles in a silica shell was introduced by Li et al. and named Shell-isolated nanoparticle-
enhanced Raman spectroscopy (SHINERS) 
78
. Some other template assisted fabrication 
methodologies include atomic layer deposition
79
 and film over nanosphere (FON) substrates 
created from deposition of thin films of Au or Ag nanoparticles on polystyrene or silica 
spheres
80, 81
. There are also some novel materials such as quantum dots
82
, graphene
83
,  and TiO2
84
 
which are coming into use as SERS substrates. However, these substrates rely primarily on the 
chemical enhancement mechanism which limits their capabilities when compared to 
conventional SERS materials
55
. Lithography techniques such and nanoimprint lithography and 
electron-beam lithography have also become powerful tools for patterning SERS substrates with 
uniform geometry. However, these techniques are often more expensive than other methods of 
fabricating SERS substrates.   
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Applications 
Surface Enhanced Raman is a powerful tool for the detection of small molecules and 
biomolecules. These SERS based sensors either use an intrinsic method where the spectra of the 
target analyte is sensed directly or an extrinsic method where a commercially available reporter 
molecule is sensed in the presence of or after interaction with the analyte. Some examples of 
applications using intrinsic sensing are CTAB coated Au-nanorods functionalized with thiolated 
beta-cyclodextrin that have been shown to detect the fungicide carbendazim at micromolar 
concentrations 
85
 and CTAB-coated nanorods have been developed as system for detection of the 
pesticide 2,4-dichlorophenoxyacetic acid 
86
. SERS has been utilized for clinical applications, as 
the Van Duyne group has made progress toward an intrinsic in vivo glucose sensor that can 
accurately measure glucose in the presence of other biomolecules
87-90
 for real time measurement 
of blood glucose levels through the skin. Intrinsic SERS has been used to address bio-warfare 
applications as well
91
. The Van Duyne group has also reported work on a SERS sensor for 
detection of calcium dipicolinate using silver FON for rapid identification of anthrax spores
92, 93
 
where silver substrates were coated with a thin layer (< 1 nm) of alumina by ALD for binding of 
the analyte to the surface
93
.   Intrinsic SERS biosensors of DNA and aptamers have also been in 
development over the last decade. Barhoumi et al. reported a method for producing reliable 
SERS spectra of DNA on Au-coated silica shells bound to glass slides by measuring the adenine 
vibrational band at 729 cm
-1 94
. Neumann et al. also showed detection of conformational changes 
in aptamers when bound to their specific targets
95
. SERS has been investigated in microbiology 
applications pertaining to identification of bacterial strains
96-98
 as well as in the study of 
cancers
88, 99-102
 and other chronic illnesses
103, 104
.    
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MOLECULARLY IMPRINTED POLYMERS 
Molecularly Imprinted Polymers (MIPs) are synthetic polymers with specific recognition sites to 
rebind a target analyte within the material scaffold
105
. These materials are comprised of 
functional monomers that are polymerized around a template molecule with cross linking 
molecules which leads to template specific cavities within the polymer matrix. MIPs have been 
prepared with binding characteristics similar to that of enzymes and immunoglobulins
106-109
. The 
template, monomers, cross linker, initiator, and method/extent of polymerization are all factors 
that need to be adjusted to achieve the desired effect of the molecularly imprinted polymer
110
. 
For example, MIPs prepared for analytical chemistry applications require highly specific binding 
cavities with low levels of unmediated diffusion out of the polymer matrix. However a drug 
delivery application might not need as strong of a binding pocket and require faster diffusion out 
of the polymer matrix
111
.  
There are three approaches to creating imprinted polymers: covalent, semi-covalent and non-
covalent
110
. The covalent approach involves a reversible covalent attachment of the template to 
the functional monomers where the bonds are cleaved and then reformed once the template 
interacts with the monomer units inside the specific cavity
112
. Covalent imprinting can only be 
used for small compounds containing alcohols, carboxylic acids, amines, and ketones
113
. 
Reaction of boronic acid with 1,2 and 1,3-diol functional groups on the templates has been 
explored in the imprinting of amino acids
114, 115
, sugars
116, 117
, carboxylic acids
118-120
. The semi-
covalent approach mirrors the covalent method except that rebinding is through non-covalent 
interactions. The advantages of semi-covalent approach are specific and more uniform 
distribution of binding sites as well as diffusion limited rebinding kinetics
113
.  
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Figure 1.2 Schematic representation of the molecular imprinting process. The imprinting process 
begins with formation of prepolymerization complex of functional monomers around template 
molecule. The functional monomers coordinating around template form a specific cavity for the 
template in the polymer matrix. Polymer synthesis by free radical polymerization proceeds after 
addition of cross linking monomer and initiator molecule. The template is finally extracted from 
the matrix and can be specifically reabsorbed.    
 
The non-covalent imprinting method was developed by Mosbach et al 
121
 where the complex 
between template and monomers during the polymerization steps is based on a combination of 
hydrogen bonding and hydrophobic interactions
111, 113
. The simplicity of the imprinting protocols 
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and availability of a variety of monomer substrates have made non-covalent imprinting the 
preferred imprinting method in the field
113
.    
Non-covalent interactions usually use an excess of functional monomers to shift the 
thermodynamics of the system to favor assembly of template/monomer complex
122
. A rule of 
thumb for template/monomer ratio is begin with a ratio of 1:4, although larger amounts of 
monomer are also used
123
. The most common functional monomer used for non-covalent 
imprinting is methacrylic acid and has been adapted for use with a variety of templates
124-126
. 
Other common monomer units are 4-vinylpyridine, 2-hydroxyethyl methacrylate (HEMA), and 
acrylamide.   
Selection of the cross linker which forms the bulk of the polymer matrix and serves to stabilize 
the binding site is critically important in MIP preparations. It determines the morphology and 
mechanical stability of the polymer scaffold
123
. High cross linking ratios (~80%) are preferred 
because it leads to a material with minimal deformation and ample stability. One of the more 
common cross linking agents, ethylene glycol dimethacrylate (EGDMA) works well at high 
cross linked ratios and has been used in a variety of drug delivery applications
127-129
. Previous 
work has shown MIPs composed of EGDMA form stable macromolecular networks resistant to 
extreme fluctuations in pH and temperature in vitro
130-133. Several studies have comparing the 
performance of EGDMA to another common cross linking agent, divinylbenzene (DVB), 
showed that polymer synthesized with EGDMA had an improved separation factor
134-136
. This 
feature is thought to arise from the fact that EGDMA is not only short and flexible but also has 
rigid centers at the methacrylate functional groups
113
.  
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MIP polymer synthesis is usually carried out using free radical polymerization due to simplicity 
of the reaction and the commercial availability to a broad range of monomer, cross linkers, and 
initiators
113
.  Azo-initiators are the standard inititators used in methacylate based MIPs. Most 
MIP preparations use the thermal decomposition of azobisisobutyronitrile (AIBN) to initiate free 
radical polymerization. 2,2’-azo-bis-(2,4-dimethylvaleronitrile) (ABDV) which has a lower 
decomposition temperature is used for low temperature polymerizations
137
. Other initiators used 
in preparation of MIPs are known as iniferter molecules (usually dithiocarbamate derivatives) 
that can act as initiator (ini), chain transfer agent (fer), and terminator (ter)
138
.  The advantage of 
using an initiator with more than one mode of decomposition is that one can change the 
polymerization conditions if the template is photochemically or thermochemically unstable 
123
.          
The solvent used for polymerization plays an important role in the formation of pores in the 
macromolecular network. The type of solvent (also called porogen) used will determine the 
morphology, porosity, swellablity, and rigidity of the final matrix
139
. The solvent also plays an 
important role in stabilization of the prepolymerization complex between template and 
monomers for non-covalent MIPs. Water in a mixture with a polar solvent such as methanol has 
been shown to promote hydrophobic interactions
140
 while increasing the organic content of a 
porogen mixture favors ionic interactions between template and monomers
141, 142
.   
Taking all of these factors into consideration, it is possible to create a molecularly imprinted 
polymer with specific recognition to a template for many applications. Molecular imprinted 
polymers for liquid chromatography
143-146
, solid-phase extraction
147-154
, sensing
155
, and drug-
delivery
105, 111
 have all been developed using non-covalent imprinting approach.      
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CONCLUDING THOUGHTS 
This dissertation research addresses or examines several needs in the fields of cancer 
immunotherapy, SERS sensing, and drug delivery. The second chapter of this dissertation 
examines strain development, process development and implementation of pilot scale cGMP 
production of the cancer testis antigen, Melan-A, for possible phase I clinical trials. The third 
chapter deals with development of a novel SERS sensor using DNA aptamers specific for the 
pesticide malathion, for rapid capture and detection of the contaminant. The fourth chapter 
focuses on a molecularly imprinted polymer for drug delivery of doxorubicin using a controlled 
release mechanism. The fifth chapter of this dissertation deals with development of a sensor 
which combines the specificity of a MIP with the analytical power of SERS to detect the 
fungicide thiabendazole. In this system the imprinted polymer is grown from the surface a gold 
coated silica particle modified with the iniferter molecule sodium diethyldithiocarbamate. The 
sixth chapter details a curriculum plan develop through the NSF GK-12 program designed to 
teach 8
th
 grade students principles of marine biology, microbiology and nanotechnology. Student 
were lead through a series of activities focused on mapping of sea turtle locations using GSP 
data, calculating the distance a sneeze travels, PCR identification of bacteria in samples taken 
from aquatic animals, and fabrication of Surface Enhanced Raman substrates using gold 
nanoparticles.     
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Chapter 2: Process Development and Production of cGMP Grade Melan-A for Cancer Vaccine 
Clinical Trials 
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ABSTRACT 
Melan-A is a cancer testis antigen commonly found in melanoma, and has been shown to 
stimulate the body’s immune response against cancerous cells. We have developed and executed 
a process utilizing current good manufacturing practices (cGMP) to produce the 6x-His tagged 
protein in C41DE3 Escherichia coli for use in Phase I clinical trials. Approximately 11 gm of 
purified Melan-A were produced from a 20 L fed-batch fermentation. Purification was achieved 
through a three column process utilizing immobilized metal affinity, anion exchange, and cation 
exchange chromatography with a buffer system optimized for low-solubility, high LPS binding 
capacity proteins. The host cell proteins, residual DNA, and endotoxin concentration were well 
below limits for a prescribed dose with a final purity level of 91%. 
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INTRODUCTION 
Melan-A, also known as MART-1, has been used as a diagnostic marker 
156
 for melanoma as 
well as an immunotherapeutic agent 
43
. This tumor associated antigen (TAA) contains 118 amino 
acids, with a 21 amino acids predicted transmembrane domain and a 92 solvent exposed 
domain
157
. Melan-A was originally cloned by Coulie et al.
158 
and was independently cloned by 
the Kawakami et al. 
159
 who termed it MART-1 (Melanoma Antigen Recognized by T-cells) 
42
. 
The protein is expressed only in melanocytes, the retina, and most melanoma cancers. While it is 
expressed in virtually all metastatic melanomas, some primary, cutaneous melanomas have 
stained Melan-A negative 
160
.  
Melan-A is a member of the MAGE gene family 
42
, which includes many TAAs  that are 
recognized by cytotoxic T lymphocytes (CTL). Once recognized, CTLs lyse the cancerous 
cell
161
.  NY-ESO-1
162
  and SSX-2 
163
 are two related TAAs which provoke similar reactions from 
CTLs and have had some success as cancer vaccines
164, 165
.  Interestingly, it has been 
demonstrated that Human Leukocyte Antigen (HLA) phenotype strongly influences the efficacy 
of Melan-A vaccination due to the ability of the HLA molecule to present the antigen 
166
. Other 
TAAs appear to be antigenic when displayed by multiple HLA phenotypes 
167, 168
.  
Melan-A peptides have been delivered through viral vectors and directly as peptide solutions for 
use as cancer vaccine antigens. Virally, Melan-A has been expressed using lentiviral 
168
, 
adenoviral 
169
, and poxviral  vector 
170, 171
 systems. The studies’ results strongly supported the 
use of Melan-A as an immunotherapy. This is especially well supported by the phase I/II clinical 
trials using inactivated vaccinia virus. Individuals have also been vaccinated with Melan-A 
 24 
 
peptides intravenously as part of clinical trials. In order to elicit a stronger CTL response, 
adjutants 
172
 and combination therapies have been used. There has been significant evidence that 
masking the CTLA-4 protein on helper T-cells can significantly increase the immune response to 
vaccine antigens 
173-175
. As with any selective agent, resistance to CTLs has been observed 
176
 
and is further evidence that combination therapies are required for these vaccine treatments.  
We have developed a process to produce His-tagged current Good Manufacturing Process 
(cGMP) grade Melan-A at the pilot-scale for clinical trials. The process utilizes a 20 L fed-batch 
fermentation and a three column purification scheme to remove contaminating host proteins and 
endotoxin. Together with the protein’s initial success in limited trials 177-180, we have filled the 
gap between laboratory and industry scale to provide cGMP grade Melan-A for use in vaccine 
clinical trials. 
MATERIALS AND METHODS 
Materials 
All materials used were obtained at the highest purity level possible.  All equipment was cleaned 
and tested in accordance with cGMP protocols detailed in the harmonized International 
Conference on Harmonisation (ICH) quality guidelines
181
. Production staff followed strict cGMP 
training and operating procedures during production of the biopharmaceutical material. Water for 
injection grade water was used for all solutions (Hyclone Inc. Logan, UT). All column 
chromatography purification steps were performed using an Akta Purifier FPLC system (GE 
Healthcare, Piscataway, NJ)  equipped with either a BPG 200/500 or 100/500 column  (GE 
Healthcare, Piscataway, NJ) controlled by Unicorn software version 4.12 (GE Healthcare, 
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Piscataway, NJ). Our production technicians packed all chromatography columns.  The columns 
were then checked for symmetry and plate count as directed by the manufacturer. Protein and 
endotoxin concentrations were measured using Bradford and Limulus Amebocyte Lysate assays 
respectively, as previously described 
182
. 
Buffer Composition 
 Lysis buffer: 50 mM Tris Base, 100 mM NaCl, 1 mM MgSO4, 1 mM -
mercaptoethanol, 2.5x10
-3 % (v/v) “Turbo” DNase (Ambion, Inc., Austin, TX) at pH 8.0. 
Solubilization buffer: 2% m/v deoxycholate (sodium salt), 1% v/v Triton-114, 8M urea, 50 mM 
phosphate, 200 mM NaCl, 100 mM KCl, 10 mM imidazole, 2.5 mM ß-mercaptoethanol at pH 
7.5. Urea buffer: 4M urea, 50 mM phosphate, 2.5 mM ß-mercaptoethanol at pH 7.5. Imidazole 
buffer: Formulated as urea buffer with 500 mM imidazole. Carbonate buffer: 4M urea, 10 mM 
Carbonate, 1 mM 2-Mercaptoethanol at pH 10.5 Carbonate elution buffer: Formulated as 
carbonate buffer with 1M sodium chloride at pH 10.5 Final Bulk Buffer: 4M urea, 50 mM 
phosphate, 145 mM NaCl, 50 mM glycine at pH 6.5. All buffers cleared endotoxin testing before 
use.    
Description of Facility 
The manufacturing facility is approximately 1,100 sq. ft. and consists of five (5) process suites: 
Bioreactor, Cell Disruption, Downstream Purification, Buffer Prep & Wash, and Storage. In 
addition there is a common hallway and a gowning room. Interlocking pass-throughs are 
positioned between the Downstream Purification Room and Cell Disruption as well as between 
the Downstream Purification Room and Buffer Prep & Wash Room. Adjacent to the 
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manufacturing suite is the mechanical room housing an oil-free air compressor for process and 
instrument air, HVAC system with dedicated air conditioners, on-demand dry steam humidifier, 
dedicated purified water-USP water system and a dedicated recirculating refrigerated chiller. The 
facility has a dedicated boiler for plant (dirty) steam.  The GMP manufacturing facility suites are 
classified as ISO level 8 with the exception of the downstream purification room which has an 
ISO classification level 7.  
Data analysis 
The standard curve, spike recovery, and sample dilutions for all quantitative assays were 
analyzed for linearity, accuracy, and intra-assay precision. For linearity, the mean corrected 
value versus expected concentration was plotted and a best fit line using linear regression 
analysis was generated. For endotoxin assay, log10 of the mean onset time versus the log10 of the 
expected endotoxin concentration was plotted. The accepted correlation coefficient and the 
residual sum of squares were ≥ 0.98 and ≥ 0.97 respectively. Accuracy was determined by 
equation 1. The accepted accuracy of the lowest standard was ±20% of its expected 
concentration and all other standards had an accepted accuracy of ±10%. The precision was 
calculated using the coefficient of variation. The accepted CV for the standard was ≤20% for the 
lowest concentration and ≤10% for all other samples. Spike recovery was calculated by equation 
2. The accepted spike recovery was within 70%-130% of the expected value.  
1.         ( )   (
                                                   
                      
)      
2.                ( )   (
                    
     
)      
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Assay Validation 
Preparation and execution of assay validation was the responsibility of the Facility Manager and 
assigned personnel. Approval of the qualification protocol and completed qualification report 
was the responsibility of Quality Assurance. All designated test instruments and standards used 
in assay validation and in the exercise of the assay were calibrated as NIST traceable where 
applicable. References used for assay validation include FDA(Food and Drug Administration)-
Code of Federal Regulations (21 CFR Part 211): Subpart I-Laboratory Controls, TGA 
(Therapeutic Goods Administration) –Australian Code of Good Manufacturing Practice for 
Medicinal Products; Chapter 6 – Quality Control, ICH (International Conference on 
Harmonization)  Q2A – Validation of Analytical Procedures, and ICH (International Conference 
on Harmonization)  Q2A – Validation of Analytical Procedures: Methodology.  
Picogreen dsDNA Quantification assay 
PicoGreen dsDNA quantitation assay was developed from Molecular Probes PicoGreen® 
dsDNA Quantitation Kit (Molecular Probes). 8 µg/mL of working solution of dsDNA was 
diluted in 1X TE working solution (10 mM Tris-HCl, 1 mM EDTA, pH 7.5). Eight dsDNA 
standards were prepared from 2000 mg/mL- 0 ng/mL. 90 µL of each dsDNA standard and 
experimental sample was loaded into the corresponding microplate well, in triplicate. Two 
dilutions of selected experimental samples were spiked with 9 µL of 8000 ng/mL dsDNA 
standard. 90 µL of 1X PicoGreen® dsDNA quantitation reagent was transfer into each well 
containing blank, standard, or sample. The fluorescence intensity of the samples at 515 nm 
(ex.485 nm) was measured on a Tecan Genios Microplate Reader (Tecan, San Jose, CA).  
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Endotoxin Quantification assay 
Endotoxin quantification assay was adapted from Endosafe® Endochrome-K™ reagent protocol. 
First, Endochrome-K™ was rehydrated in 3.2-3.4 mL of LAL reagent water. Endosafe® Control 
Standard Endotoxin (CSE) was reconstituted in manufacturer specified volume using LAL 
reagent water to a final concentration of 50 EU/mL. Standards were prepared in depyrogenated 
glass test tubes and vortexed for 30 seconds.  If necessary, samples were diluted with LAL 
reagent water until concentrations were within the range of the standard curve. Dilutions were 
based on the calculated Maximum Valid Dilution (MVD) where MVD = (Endotoxin Limit x 
Product Potency)/λ. 10 µL of 5 EU/mL CSE spike for each selected experimental sample was 
loaded into the corresponding microplate well, in triplicate, prior to adding the sample. 0.1 mL of 
endotoxin standard and experimental samples is added to the corresponding wells, in triplicate, 
as defined by the S.O.P. 100 µL of LAL is added to each well and the absorbance is measured at 
405 nm using a Tecan Genios Microplate reader (Tecan; San Jose, CA). Endotoxin limit for the 
bulk drug substance is calculated as K/M; where K is the maximum human pyrogenic dose of 
endotoxin per kg of body weight (5 EU/kg) and M is the maximum recommended human dose 
per kg of body weight per hour. The dosage levels for Melan-A were taken from recommended 
dosage levels in clinical trials involving Melan-A 
179, 180
.  
NanoLC-MS/MS analysis 
Peptide mapping and purity levels were determined by mass spectrometry. All assays and data 
analysis were completed by the Proteomics and Mass Spectrometry Core Facility at Cornell 
University. A sample from each final filtered bulk was analyzed by direct in-solution digest with 
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trypsin and separated by a nano-HPLC interfaced with a LTQ Orbitrap Velos Hybrid FT mass 
spectrometer (Thermo Scientific). The CID fragmentation method was used for both samples. 
The raw data files were screened using the Mascot search engine against the NBCI database.  
Purity levels were estimated by the Exponentially Modified Protein Abundance Index (emPAI) 
method 
183
 
Plasmid & Strain Development 
The Melan-A gene is 357 base pairs encoding a protein of 118 amino acids with a deduced mass 
of 13.2 kDa. Sequence coding for a polyhistidine-tag was added to the 3’ end of the codon 
optimized Melan-A gene. The modified Melan-A gene was synthesized by Integrated DNA 
Technologies (IDT) (Coralville, IA). Its sequence was determined by Sanger (3730XL) DNA 
sequencing and the resulting 124 amino acid sequence with a deduced mass of 13.9 kDa was 
deposited in Genbank under accession number NM_005511.1.   
The expression construct was obtained by digesting the pET9a24a and IDT Melan-A plasmid 
with NdeI and NotI, and isolating the fragments of 4.5 kb and 0.4 kb respectively.  The DNA 
digest was then separated by gel electrophoresis using a low melting point, 1% agarose gel and 
purified using a Wizard PCR Preps kit (Promega).The two DNA fragments were then ligated 
together and transformed into TOP10F’cloning strain, (Invitrogen).  The transformed cells were 
plated on LB plates containing 100 mg/L kanamycin.  One colony was selected, grown in LB 
broth with 100 mg/mL kanamycin and the DNA plasmid isolated using a Wizard Plus SV 
Miniprep kit (Promega). The resultant plasmid is pET9a24a-Syn-Melan-A. Plasmids were then 
characterized by digestions with NdeI and BamHI indicating the presence of Melan-A insert, and 
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by digestion with ClaI and PstI showing the correct orientation of plasmid. The expected 4.5 kb 
and 0.4 kb bands for NdeI/BamHI digest, and 3.3 kb and 1.5 kb bands for ClaI/PstI digest were 
observed. The Melan-A gene in the expression plasmid was sequenced with four fold 
redundancy, two forward and two backward sequencing reactions. The amplification primers 
used were T7-F: 5’-taatacgactcactataggg-3’ and T7-R: 5’-caaaaaacccctcaagacccgttta-3. Host 
strain characterization was carried out following protocols provided by Lucigen (Middleton, 
WI). C41(DE3) and BL21(DE3) expression strains were transformed with the pAVD10 
expression vector and were plated onto APS LB plates containing 100 µg/ml ampicillin with and 
without 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG).  The plates were then incubated 
overnight at 37 °C and the resulting colonies observed. No colonies should be observed on plates 
containing IPTG induced C41 strain.   
The transformation was carried out by incubating 50 µl of purchased competent C41(DE3) cells 
on ice. 100-200 ng of the expression vector, pET9a24a-Syn-Melan-A was added to C41(DE3) 
competent cells. The cells were put in a 0.1 cm gap cuvette and eletroporated at 25F, 200 Ohms 
and 1500 Volts for 3 to 4 msec.  Within 10 second after the pulse, 975 L of SOC media was 
added to cuvette. The cells were gently mixed and placed in a sterile tube to incubate at 250 
rpm/37 °C for an hour.  50L of the transformed cells were spread on APS-LB Agar containing 
100 g/ml of kanamycin. The plates were then incubated at 37 C overnight and kanamycin-
resistant colonies were selected. Four transformants were selected and placed into 5 mL of the 
fermenter medium in sterile 50 mL conical bottles.  The cells were grown overnight at 25 C 
with shaking at 200 rpm.  Aliquots of the cultures were transferred aseptically into fresh 5 mL of 
medium in conical tubes, so that the final OD600 was about 0.1-0.2.  The cultures were allowed to 
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grow at 37 C with shaking at 250 rpm to an OD600 of 0.5-1.0.  The cultures were then induced 
with IPTG at a final concentration of 0.4 mM and allowed to grow for 4 more hours.  The culture 
with the highest yield of Melan-A was selected for 250 ml scale expression screening 
experiments.  
For scale up expression screening, an aliquot of an overnight culture was transferred to 50 mL of 
bioreactor medium in a 250 mL baffled flask (Nalge Nunc), so that the OD600 was about 0.1 to 
0.2.  The culture was allowed to grow at 37 C with shaking at 250 rpm to an OD600 of 0.5-1.0.  
After removing 15 mL of the culture as the uninduced sample, IPTG was added to the remainder 
to a final concentration of 0.4 mM and allowed to grow for 4 hours. Equivalent amounts of cell 
pellet were then aliquotted, lysed and resolved on commassie stained SDS-PAGE and Anti-
Melan-A western blot.   
The Melan-A expression strain was grown for 16S ribosomal DNA analysis.  A single colony 
was grown overnight at 37 ºC with shaking in 5 mL of APS LB containing 100 µg/ml of 
kanamycin.  Genomic DNA was obtained using a DNeasy Tissue Kit (Qiagen; Valencia, CA). 
The ~1.5 Kb 16S rRNA gene sequence was amplified using the following forward and reverse 
primers: 5’-AGA GTT TGA TCC TGG CTC AG-3’ and 5’-AAG GAG GTG ATC CAA CCG 
CA-3’, respectively. The PCR protocol began with a 10 minute denaturing step at 94 ºC. A PCR 
cycle consisting of a 30 second denaturing step at 94 ºC, a 30 second annealing step at 51 ºC, and 
a 2 minute elongation step at 72 ºC was repeating 29 times. The PCR reaction finished with a 
final extension step at 72 ºC for 10 minutes and was maintain at 4 ºC until it was removed from 
thermocycler.  The PCR product was cloned using a TOPO® TA cloning® kit (Life 
Technologies, Cal).  Two colonies were picked from each plate and these cultures were grown 
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overnight at 37 ºC.  The plasmid DNA was then purified via minipreps (Promega; Fitchburg WI) 
and the insert confirmed by digestion with EcoRI.  The resulting DNA was then sequenced at 
both ends using the M13 reverse and T7 high temp primers (M13R:5’-
AACAGCTATGACCATG-3’, T7H:5’-GTAATACGACTCACTATAGGGC-3’). The sequences 
were compared to the published BL21 16S rRNA sequence, accession # AJ605115. Although 
there were several point mutations, no significant deviations from the control sequences were 
detected.     
Single colonies of the expression strain were selected and placed into 5 ml of the bioreactor 
medium in sterile 50 ml conical tube.  The cells were grown overnight at 25 C with shaking at 
250 rpm.  Aliquots of the cultures were then taken and transferred aseptically into fresh 5 ml of 
medium in conical tubes, so that the final OD600 was about 0.1.  The cultures were allowed to 
grow at 37 C with shaking at 250 rpm to an OD600 of 1.0-1.5. 1 ml of cell culture was aliquoted 
into cell bank cryovials and sterile 80% glycerol was added to a final concentration of 10 % 
(v/v). Cells were then placed into a -80 C freezer immediately for storage.   
A vial containing the transformed C41 strain was obtained from the bioprocess research 
laboratory and the contents were plated on solid growth medium containing 100 μg/ml 
kanamycin.  Plates were then incubated at 37ºC until the colonies were 1-2 mm in diameter. A 
single colony from a plate was selected and transferred to a 50 mL conical tube containing 5 mL 
of liquid growth medium containing 100 μg/ml kanamycin and 34 μg/ml chloramphenicol. The 
inoculum was incubated with shaking (250 rpm) at 25°C overnight. One mL of the overnight 
culture was transferred into a 125 mL flask containing 25 mL of the liquid growth medium, 100 
μg/mL of kanamycin and 34 μg/mL chloramphenicol. The inoculum was incubated with shaking 
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at 37ºC for 2-3 hours or until and OD600 of 0.5 to 1.0 was reached. The inoculum was used to 
prepare the Master Cell Bank (MCB). The inoculum was aseptically mixed with sterile glycerol 
(9 parts culture: 1 part 80% glycerol) and dispensed as 1 mL aliquots into tubes compatible with 
storage in an ultra-low freezer. The master cell bank vials were frozen for 48 hours before 
proceeding with establishment of the working cell bank.  
A single vial from the MCB was thawed and the contents used to inoculate a 50 mL conical tube 
containing 5 mL of liquid growth medium (see table in section 2.4.4.1) containing 100 μg/mL 
kanamycin. The inoculum was incubated with shaking (250 rpm) at 25°C overnight. The 5 mL 
overnight culture was added to 50 mL of liquid medium, 100 μg/mL of kanamycin in a 250 mL 
flask. The inoculum was incubated with shaking at 37ºC for 4-6 hours or until an OD600 of 0.5 
to 1.0 was reached. Cells were aseptically mixed with sterile glycerol (9 parts culture to 1 part 
80% glycerol) and dispensed as 1 mL aliquots into tubes compatible with storage in an ultra-low 
freezer. Master and working cell banks were produced from the research cell bank and 
characterized by Gram Stain Analysis, Microscopic Purity Identification, Plasmid Stability, 
Escherichia coli Identity Test, 16S rDNA Analysis (UV, agarose gel, and sequencing), Plasmid 
DNA Analysis (UV, agarose gel, and sequencing), Protein Quantitation by Bradford, SDS-
PAGE, and Western Blot analysis before cGMP production. 
Fermentation 
A 1 ml vial from the working cell bank was used to inoculate 50 ml of production culture 
medium, as described in a previous report 
182
, in a sterile 250 ml flask. The culture was shaken at 
250 rpm overnight at 37˚C. The entire culture volume was then aseptically inoculated into 350 
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ml of production medium in a sterile 2 L shake flask. Cells were shaken at 37˚C for two hours, 
after which they were aseptically inoculated into a 25L BioFlo 4500 Bioreactor (New Brunswick 
Scientific, New Brunswick, NJ) containing 7L of production media. AFS-Biocommand 
Bioproessing software version 2.6 (New Brunswick Scientific, New Brunswick, NJ) controlled 
the fermentation and logged all reaction conditions. During fermentation, dissolved oxygen (DO) 
was maintained at 40% of saturation and was controlled by a DO cascade of agitation  
(maximum of 1000 rpm) followed by supplementation with pure oxygen as needed. The 
temperature, pH, and gas flow were set to 37°C, 6.8, and 20 standard liters per minute 
respectively. A solution of 5M NaOH controlled the reactor pH during the batch phase. Upon 
exhaustion of the glucose in the batch phase, the base feed was turned off and 12.5 L of glucose 
feed containing 1M IPTG was initiated, as previously formulated 
182
. A pH-stat feedback 
mechanism regulated the feed rate by feeding in a controlled volume of feed (acid) in response to 
an increase in pH inside the bioreactor as a result of accumulation of ammonium ions.   
Harvest & Lysis 
The fermentate was harvested into a sterile 20 L Hyclone® bioprocess bag , and then fed into a 
Carr Powerfuge Pilot (Pneumatic Scale Corp., Cuyahoga Falls, OH) operating at 14500 rpm, 
from which the cell pellet was periodically collected, once the powerfuge bowl was full (approx. 
1L of solids). The powerfuge was cleaned, reassembled and an additional volume of fermentate 
was fed into the powerfuge until the bowl was full of solids. This process was repeated until the 
entire fermentate was processed. The centrate discharge was analyzed during operation to 
determine when bowl was full by checking for accumulation of solids in the supernatant.  
Approximately one half of the concentrated biomass was frozen at -20°C to be processed later, 
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while the second half was resuspended in 15 L of lysis buffer. Portions of the cell suspension 
were sequentially disrupted in a 4 L Waring laboratory blender and transferred to a clean, sterile 
bioprocess bag. The disrupted cells were subjected to three passes through a Microfluidics 
Microfluidizer M100EH (Microfluidics International Corp., Newton, MA) at 23 Kpsi.  
Solubilization and Filtration 
The lysate was solubilized for 18 hours while mixing in 35 L of solubilization buffer. The 
solution was then passed through a 10” 1.2 µm low protein binding filter (LPBF) (Millipore 
Corp., Billerica, MA) and subsequently a 10” 0.5 µm LPBF (Millipore Corp., Billerica, MA).  
Immobilized Metal Affinity Chromatography (IMAC) & Buffer Exchange 
All chromatography was carried out using an Akta Purifier FPLC (GE Healthcare, Piscataway, 
NJ) controlled by Unicorn software (GE Healthcare, Piscataway, NJ). The 42L of filtered lysate 
was loaded at 90,800 cm/hr onto a 5 L column containing nickel-bound Chelating Sepharose 
Fast Flow resin (GE Healthcare, Piscataway, NJ), previously equilibrated with two column 
volumes (CV) of solubilization buffer. Each chromatography fraction was collected into sterile 
bioprocess bags. The purification program used the scheme: 11 CV load, 7 CV solubilization 
buffer wash, 5 CV urea buffer wash, 5 CV 15% imidazole buffer diluted into urea buffer, and 3 
CV elution with 100% imidazole buffer. The elution fraction was concentrated to 1 L using a 
Millipore ProFlux M12 TFF system with two 4 KDa Centramate cassettes (Pall). The retentate 
was then exchanged five-fold volumetrically with carbonate buffer and collected into a sterile 
bioprocess bag. The M12 system was run at 25% pump speed producing an inlet pressure of 30 
PSI and outlet pressure of 20 PSI for both the concentration step and diafiltration step.  
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Anion & Cation Exchange Chromatography (AXC & CXC) 
A 1 L column containing Q Sepharose XL resin (GE Healthcare, Piscataway, NJ) was 
equilibrated for 3 CV at 50 mL/min with carbonate buffer. The retentate was then loaded with 
carbonate buffer at a 70:30 ratio at 45,400 cm/hr for 3.8 CV. The protein was then washed with 
2.5 CV of carbonate buffer and subsequently eluted with 5 CV of carbonate elution buffer. Each 
fraction was collected in a separate, sterile bioprocess bag.  The cation exchange column was 
conducted as a flow through column using 45,400 cm/hr as a constant flow rate. The column was 
equilibrated with 2 CV carbonate elution buffer then was loaded with the anion exchange elute 
for approximately 5 CV. The column was then washed out with 1.5 CV of carbonate elution 
buffer. The load flow-through and the wash out fractions were collected into a single, sterile 
bioprocess bag.   
Final Buffer Exchange and Terminal filtration 
The fraction collected from the cation exchange column was concentrated to 1 L as described 
above in an M-12 TFF system and then buffer exchanged with 6 L of final bulk buffer. The 
system was flushed with 500 ml of final bulk buffer to collect any residual protein for a final 
retentate volume of ~1.5 L. The protein solution was then passed through a sterile 0.22 µm disc 
filter (Millipore) under sterile conditions into a bioprocess bag for storage.  
RESULTS AND DISCUSSION 
Plasmid and Cell Bank Construction 
A synthetic version of Melan-A was developed to aid in its production in the host system and 
purification using affinity based column chromatography. The DNA sequence was codon 
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optimized for E. coli to avoid stringent responses from amino acid starvation due to codon bias 
184
. The synthetic Melan-A sequence was further modified with a 6x-polyhistidine tag on the C 
terminus for purification. This version of Melan-A (Syn-Melan-A) has 375 base pairs encoding 
124 amino acids with a mass weight of 14.1 kDa.  The expression plasmid was constructed from 
the Syn-Melan-A insert and the pET9a24a plasmid (Figure 2.1A). The C41 strain of E. coli 
derived from BL21 was used as the host expression strain for its ability to produce high levels of 
membrane-derived recombinant proteins 
185
.  It has the genotype F- ompT hsdSB (rB- mB-) gal 
dcm lon and one uncharacterized mutation which inhibits cell death resulting from expression of 
toxic recombinant proteins. To characterize the host expression strain, an expression based 
selection system using a plasmid verification vector was used to select for C41(DE3). The 
pAVD10 vector contains uncF gene which encodes for the beta-subunit of E. coli ATPase under 
control of the T7 promoter. This vector is lethal to BL21 and induced C41(DE3). No C41(DE3) 
colonies were obtained in the presence of 1 mM IPTG. The BL21(DE3) strain did not grow 
under either condition.  The host strain was then transformed and selected for kanamycin 
resistance.  
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Figure 2.1 a) pET9a24a plasmid map containing Syn-Melan-A. b) (i) Commassie stained SDS-
PAGE and (ii) Anti-Melan-A western blots of four tested Melan-A expression strains. M, 
molecular weight marker; S, Melan-A standard; B, before Melan-A induction cell lysate; 1 to 4 
indicate the after induction cell lysate of four different transformants. c) (i) Coommasie stained 
SDS-PAGE and (ii) Anti-Melan-A western blots of strain numbered 4 expression Melan-A. M, 
molecular weight marker; S, Melan-A standard; B, before Melan-A induction cell lysate; I, after 
induction cell lysate. d) PCR amplification of 16S DNA of Melan-A expression strain number 4.  
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Expression screening was carried out by selecting four kanamycin resistant colonies and growing 
the colonies in 5 ml of bioreactor media at 37 ºC. Melan-A expression was induced with the 
addition of IPTG for four hours after which the cell pellet was lysed and equivalent amounts of 
lysate from each colony were analyzed by commassie stained SDS-PAGE (Figure 2.1Bi) and 
Anti-Melan-A western blot (Figure 2.1Bii). Colony number four (N4) showed the highest level 
of expression and was selected for 50 ml level expression screening. 
Larger scale expression screening was carried at the 50 ml scale.  The culture was grown at 37 
ºC/250 rpm until an O.D. of 0.5-1.0. 15 ml of the culture were removed as the T0 sample and 1 
M IPTG was added to the remaining media to final concentration of 4 mM. The culture was 
induced for four hours and the cell pellet harvested. Figure 2.1Ci & ii shows a commassie stained 
SDS-PAGE and anti-Melan-A western blot for the 50 ml expression screen with the Melan-A 
monomer band at 14 kDa appearing in the induced sample.  Next, transformant N4 was grown 
for 16S rDNA sequencing for species identification. The gene for 16S rRNA was amplified by 
PCR using methods adapted from Martinez-Murcia et al 
186
.  The ~ 1.5 Kb PCR product was 
analyzed by gel electrophoresis (Figure 2.1D) and subsequently subcloned into a Topo TA 
vector. Two transformed colonies were isolated from each plate and the plasmid DNA was used 
in an analytical digestion with EcoRI to confirm correct insertion of the insert. The plasmid was 
then sequenced using the M13 reverse and T7 high temperature primers. The entire 16s region 
was sequenced twice in the forward and reverse directions for a total of 4 fold coverage.  The 
sequences were then compared to a published BL21 16 sequence (accession # AJ605115).  
Although there were several point mutations, no significant deviations from the control 
sequences were detected. Isolated colonies from this strain were grown designated as the 
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research cell bank.  Master and working cell banks were established from the research cell bank.   
After the master and working cell banks were established, vials were tested according to 
validated SOPs. Two random vials were selected from each bank for characterization testing. In 
addition, one research vial was selected from the bioprocess research laboratory as a control, 
labeled Melan-A in pET9a24a in C41 (DE3).  The vials were cultured and examined 
microscopically to verify that the cells were rod shaped with no apparent contamination. The 
Melan-A cell banks as well as the research vial met all acceptance criteria. 
Fermentation 
The fed-batch fermentation was conducted under pH control using a feedback control loop. The 
DO, pH, glucose feed volume, base feed volume, and oxygen flow rate were all recorded during 
vessel preparation and post-inoculation. The vessel was inoculated at hour 21 of the 
fermentation. The batch phase is marked by acidification of the medium by the cells triggering 
addition of a P.I.D. controlled volume of sodium hydroxide into the vessel to maintain pH at 6.8. 
After approximately 30 ml of base was added to the vessel, the glucose feed loop was initiated 
and base was not added until the pH of the media rose above the set point.  As shown in Figure 
2.2, the dissolved oxygen concentration (DO) begins to plummet at hour one into the 
fermentation indicating initiation of glucose consumption by the cells. The DO concentration 
then spiked 4 hours after induction indicating an exhaustion of the initial carbon source in the 
bioreactor medium. As the bioreactor medium pH increases due to an accumulation of 
ammonium ions after the depletion of the primary carbon source 
187, 188
, we used this process 
variable to control the glucose feed rate into the vessel. The glucose feed, containing IPTG, was 
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introduced into the vessel using empirically determined proportional control algorithm that 
resulted in a constant growth rate during the induction process. Oxygen was supplemented to 
maintain the dissolved oxygen level at 40% during the feed stage. The cells were deemed ready 
to harvest when the DO levels continued to rise above the set point despite additional feed. The 
fermentation completed reproducibly after 23 hours with the consumption of 12 L of glucose 
feed. The final wet cell weight prior to lysis was 245.81 g/L. Table 2.1 details the optical 
densities and wet cell weights for each of the steps in the fermentation process. A single 
fermentation produced enough biomass for two pilot scale GMP production batches. 
 
Figure 2.2 Fermentation profile for Melan-A. Dissolved oxygen concentration (solid line) 
follows the profile seen for pH stat control. Glucose feed (dash line) increases exponentially at 
the conclusion of the batch phase of the fermentation. 
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Table 2.1 Profile of fermentation process including optical density and wet cell weight. 
 
Sample 
Description 
OD600 Reading OD600 Neat 
Sample 
Wet Cell 
Weight (g/L) 
Pre-Inoculum 0.962 9.62 NA 
Inoculum 0.328 3.28 NA 
Before Feed 0.335 3.35 21.426 
Before 
Harvest 
0.839 167.8 237.47 
Harvest 0.845 169.0 245.81 
 
Purification 
Half of the cell pellet from the harvest was lysed in a microfluidizer to release inclusion bodies 
containing Melan-A. The cell lysate was mixed with lysis buffer to a final ratio of 4.0 kg 
buffer/kg solids. The lysate was solubilized in phosphate buffer containing 8M urea, 1% Triton-
114 and 2% w/v deoxycholate for 16 hours. The solution was then filtered through a 1.2 µm and 
0.5 µm low-protein binding capsule filter and 42 L loaded onto a 5L nickel column. Immobilized 
metal affinity chromatography (IMAC) was used as the initial purification column for Melan-A. 
The chromatogram in Figure 2.3A shows the results for the IMAC purification. Following a 
protocol developed previously by our group 
162
, the solubilized lysate was loaded onto the 
column (Figure 2.3AI) and subsequently washed with a solution of 8M urea, 2% w/v 
deoxycholate, and 1.0% v/v Triton X-114 (figure 2.3AII) which lowered endotoxin concentration 
from 197 EU/µg in the IMAC load to 0.4 EU/µg in the subsequent urea wash (Table 2.2). As 
described in our previous reports, we determined that the therapeutic antigens SSX-2, Melan-A, 
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and NY-ESO-1 bind the lipopolysacchrides produced by E. coli to high concentrations 
162, 189
. 
For example, the CT-antigen NY-ESO-1 had endotoxin levels at 1,362.95 EU/µg prior to loading 
onto the IMAC column. Additionally NY-ESO-1 had latent endotoxin which gradually diffused 
out during storage if a deoxycholate wash step was not included in the IMAC purification 
162
.  
Despite Melan-A solubilized inclusion bodies having a 10,000 fold lower endotoxin 
concentration as compared to NY-ESO-1 (197.0 EU/µg in IMAC load); even at these 
concentrations, the detergent wash step on the IMAC is essential to reduce endotoxin before the 
downstream columns as the regulatory limit for endotoxin is 1.7 EU/µg for 115 µg dose of drug 
substance. Table 2.2 details the endotoxin levels measured at several points in the purification 
process. For the two GMP batches, the majority of the endotoxin eluted either with the host 
proteins in the load flow through or in the deoxycholate wash step. The excess detergent on the 
column was washed away with an 8M urea buffer.  It is important to remove as much of the 
residual detergents as possible before downstream processing as these contaminants are difficult 
to separate from the bulk material even by rigorous buffer exchange. The detergents used in our 
process contribute to an elevated 280 nm absorbance (Figure 2.3AII) that plummeted after 1.5 
column volumes of urea wash. A small amount of endotoxin is removed in this step as well 
(Table 2.2). Using our purification scheme, the endotoxin levels were reduced to 6.7*10
-4
 EU/µg 
in the IMAC High Imidazole elution. The quality of the IMAC purification was analyzed by 
Coomassie gel and Anti-Histidine western blot. As shown in figure 2.3B, a large portion of the 
host proteins elute in the load flow through (lane 4) but no his-tagged product was lost in the 
flow through as shown in figure 2.3C (lane 4). The deoxycholate wash removes a small fraction 
of target protein (not shown) and an undetectable level of protein exits in the urea wash step 
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(figure 2.3B, lane 6). Approximately, 13 grams of total protein were collected in the high 
imidazole elution with very low levels of endotoxin which is an improvement in both yield and 
endotoxin purity when compared to our previously reported IMAC purification of NY-ESO-1. 
The eluted product was concentrated to 1 L and buffer exchanged using tangential flow filtration 
(TFF) into 10 mM carbonate buffer for anion exchange chromatography.   
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Figure 2.3 a) Immobilized metal affinity chromatography (IMAC) column chromatogram for 
Melan-A. Sections I-V correspond to load, deoxycholate wash, urea wash, low imidazole, and 
high imidazole respectively.  b) Coomassie stained SDS-PAGE gel for IMAC column 
purification steps. Lanes 1-10 correspond to protein ladder (1), Load (2), blank (3), Load flow-
through (LFT)  (4), blank (5), Urea flowthrough (UFT) (6), blank (7), IMAC low imidazole (8), 
blank (9), and IMAC high imidazole (10). c) Anti-Histidine Western Blot for IMAC column 
purification. Lane 1-10 correspond to protein ladder (1), Load (2), blank (3), LFT (4), blank (5), 
UFT (6), blank (7), IMAC high imidazole (8), blank (9), IMAC low imidazole (10). Samples 
were analyzed under reducing conditions. Primary antibody was diluted 1/20,000. The Melan-A 
monomer band appears at 14 kDa.  
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In our previous report on the production of NY-ESO-1, an anion exchange column was used as a 
flow though column followed by final polishing with a hydrophobic interaction column (HIC). 
During process development for Melan-A, we found the HIC column to be impractical for 
purification of Melan-A due to inefficient elution off of the column even with the addition of 
non-polar excipients. Additionally, detergent or alcohol removal after the HIC column is 
extremely difficult and results in a significant loss of product. Therefore, the downstream 
polishing column process was improved by converting the AXC into an elution column and 
replacing the HIC with a flow through cation exchange column.  Figure 4A shows the 
chromatogram of the AXC purification. The retentate from the post-IMAC buffer exchange was 
loaded onto the column in a 70:30 dilution ratio (V/V) with carbonate buffer. This dilution step 
allowed for increased loading capacity of the column compared to undiluted load by preventing 
resin fouling at the top of the column. The product is eluted over six column volumes with 
carbonate buffer containing 1M NaCl (Figure 2.4A-IV). Figure 4C shows a Coomassie stained 
SDS-PAGE gel of samples from the AXC polishing step. There was a slight loss of protein in the 
load flow through (Table 2.2) and no detectable loss of total protein in the wash step (figure 
2.4C). Most of the Melan-A monomer is collected in the AXC elution.  
For cation exchange, the column was equilibrated with two column volumes of the AXC elution 
buffer to ensure no binding to the column by the product. In this instance, the net negative charge 
of the protein and competition from other charged species would cause the product to flow 
through the cation resin. The product flow through was collected over 6.0 column volumes, 
which includes 1.0 column volumes of washout with AXC elution buffer (Figure 2.4B). The 
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CXC flow through was concentrated and buffer exchanged into the final formulation bulk buffer. 
Figure 2.4D shows the Coomassie gel of samples from CXC column flow through and final bulk 
retentate. The permeate fraction had no detectable levels of protein by SDS-PAGE and only a 
negligible amount of protein (0.03 mg/ml) was detected by Bradford. The product was subjected 
to dead-end sterile filtration through a 0.22 µm disk filter for final storage. Dead-end filtration 
resulted in a 15% loss in protein concentration (Table 2.2). Other types of filters were explored 
during process development, in particular low protein binding capsule filters that would reduce 
the percent loss of product in the final filtration. However, the filter used for final filtration was 
the only filter that could pass our validated bubble point test protocol needed for regulatory 
compliance.       
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Figure 2.4 a) Chromatogram for anion exchange chromatography. Section I-III are column 
equilibration, load flow through and wash respectively. Section IV shows the elution peaks for 
Melan-A with 1M NaCl. b) Chromatogram for cation exchange chromatography. The antigen 
flows through the column in section II and the wash is completed in section III c)  Coomassie 
stained SDS-PAGE gel for anion exchange column. Lanes 1-8 are as follows: protein ladder (1), 
blank (2), blank (3), AXC elute (4), blank (5), AXC load flow through (6), blank (7), AXC wash 
(8). d) Coomassie stained SDS-PAGE gel for cation exchange chromatography and final buffer 
exchange. Lane assignments (1-8) are as follows: protein ladder (1), blank (2), blank (3), CXC 
flow through (4), blank (5), final concentration permeate (6), blank (7), final bulk retentate (8). 
Samples were analyzed under reducing conditions. The Melan-A monomer appears at 14 kDa. 
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Table 2.2 Endotoxin, protein concentration, and % monomer measured during several points in 
the production process.  Endotoxin limit is 1.7 EU/µg for a dose of 115 µg.  
 
 
Sample Description 
Average 
Protein 
Concentration 
(mg/ml) 
Average Endotoxin 
Concentration 
(EU/µg Melan-A) 
% 14 kDa 
band 
IMAC Load 9.2 197 32% 
IMAC Load Flow Through 4.9 405 13% 
Deoxycholate Wash 1.9 7.89 -- 
Urea Wash  2.5*10
-2
 4.0*10
-1
 -- 
IMAC High  0.9  6.7*10
-4
 63% 
AXC Load Flow Through 0.1 1.4*10
-2
 -- 
AXC Elute 1.7 9.0*10
-3
 53% 
CXC Flow Through 0.98 1.3*10
-2
 44% 
Final Bulk Buffer Retentate 4.6 1.1*10
-2
 41% 
Filtered Final Bulk Melan-A 3.9 6.4*10
-3
 38% 
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Product Quality Testing 
In accordance with ICH guideline Q6B 
190
 for process related impurities derived from cell 
substrates in biotechnological products, we tested the final product for host cell proteins and 
residual DNA. Various processing points in the two GMP batches were analyzed by anti-E. coli 
western blot for the presence of E. coli surface antigens. As shown in figure 2.5A & B the only 
samples that contain E. coli antigens are the crude lysate and crude filtrate (IMAC load). The 
levels of host proteins were below the detectable limit of the assay in all of the samples after the 
IMAC load, including in the final product, confirming loss of host proteins in the IMAC 
deoxycholate and urea wash steps (Table 3). Residual DNA was analyzed in several process 
samples using Pico Green dsDNA reagent. The specification limit for residual DNA in the bulk 
API is ˂ 1ng/dose and for both GMP batches the final filtered Melan-A product contained ˂ 
0.002 ng/dose (330 µg) of dsDNA (Table 3). 
 A final summary Coomassie gel and Western blot for both GMP batches are shown in figure 
2.6. The bands were quantified by SDS-PAGE image densitometry using ImageJ software. The 
intensity of the 14 kDa monomer band peaks in the IMAC high (Table 2); suggesting that this 
step provides a majority of the purification of the monomer. The downstream purification steps 
show retention of monomer and higher molecular weight oligomers.  The Melan-A monomer is 
38.0 % of the total protein in the final the final filtered bulk API as estimated by gel 
densitometry. To further characterize the final product, a sample of final filtered bulk product 
from each GMP batch was analyzed by mass spectrometry for peptide mapping and purity. The 
N-terminal peptide MPREDAHFIYGYPK and C-terminal peptide LSAEQSPPPYSPHHHHHH 
of Melan-A were manually identified and verified in both batches (Table 3).  An average purity 
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level of 91% was calculated for Melan-A with the remaining percentage of protein divided 
amongst trace level of E. coli proteins (Table 3). Among the host strain contaminants are protein 
chain elongation factor -Tu, glutamine synthetase, and chaperone Hsp70.  Chaperone Hsp70 
(DnaK) has been shown to be strongly associated with bacterial inclusion bodies (IB) and EF-Tu 
is commonly associated with DnaK in inclusion bodies 
191-193
.  A total yield of 11.1 g of product 
was produced from the campaign. Endotoxin levels in the final filtered product were less than 
0.01 EU/µg which was two orders of magnitude below the 1.7 EU/µg for a 115 µg dose (Table 
3).  
Table 3 Analysis of GMP batches of Melan-A Protein Drug Substance 
Assay Specification/Limit CULICR11302010-Melan-
A 
CULICR11302010-2-
Melan-A 
Total Yield Report 6.3 g 4.8 g 
SDS-PAGE Percent ~14 kDa monomer 36.38%  40.49% 
Western Blot Major band at ~14 kDa 14 kDa 14 kDa 
Anti-E. coli Western Blot Report None Detected None Detected 
Purity by MS Report 92.27% total Melan-A 90.48% total Melan-A 
 
N-Terminal Sequencing 
Consistent with 
theoretical 
sequence 
 
Complies 
 
Complies 
 
C-Terminal Sequencing 
Consistent with 
theoretical 
sequence 
 
Complies 
 
Complies 
MW by Mass Spec. 13.980 kDa 13.434 kDa 13.434 kDa 
Residual DNA < 1 ng/dose < 0.002 ng/dose < 0.002 ng/dose 
Endotoxin ≤ 1.7 EU/µg < 0.01 EU/ µg < 0.01 EU/ µg 
Appearance Report Clear, colorless, free 
of visible particulates 
Clear, colorless, free 
of visible particulates 
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Figure 2.5 a) Anti-E.coli Western Blot of several process samples from first GMP run. Lane 
assignments (1-10) are as follows: protein ladder (1), crude lysate (2), Filtrate (3), IMAC low 
imidazole (4), IMAC high imidazole (5), Post IMAC TFF retentate (6), AXC elute (7), CXC 
flow through (8), CXC bulk purified Melan-A (9), Final Filtered Melan-A (10). b) Anti-E.coli 
Western Blot of several process samples from second GMP run. Lane assignments (1-10) are as 
follows: protein ladder (1), crude lysate (2), Filtrate (3), IMAC low imidazole (4), IMAC high 
imidazole (5), Post IMAC TFF retentate (6), AXC elute (7), CXC flow through (8), CXC bulk 
purified Melan-A (9), Final Filtered Melan-A (10). Samples were analyzed under reducing 
conditions and primary antibody was prepared at a 1/5000 dilution.  
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Figure 2.6 a) Coomassie stained SDS-PAGE gel summarizing  the first GMP production run of 
Melan-A. Lane assignments (1-12) are as follows: protein ladder (1), blank (2) crude lysate (3), 
Tris Permeate (4), IMAC Load (5) IMAC low imidazole (6), IMAC high imidazole (7), post 
IMAC TFF retentate (8), AXC elute (9), CXC flow through (10), final bulk retentate (11), final 
filtered Melan-A (12). b) Anti-Histidine western blot of Melan-A summary gel for first GMP 
run. Lane assignments (1-12) are as follows: protein ladder (1), blank (2) crude lysate (3), Tris 
Permeate (4), IMAC Load (5) IMAC low imidazole (6), IMAC high imidazole (7), post IMAC 
TFF retentate (8), AXC elute (9), CXC flow through (10), final bulk retentate (11), final filtered 
Melan-A (12). c&d) Coomassie stained SDS-PAGE summary gel and Anti-Histidine western 
blot of second GMP production run. Lane assigments are protein ladder (1), blank (2), crude 
lysate (3), IMAC load (4), IMAC low (5), IMAC high (6), IMAC LFT (7), blank (8), post IMAC 
TFF retentate (9), AXC load FT (10), AXC elute (11), CXC flow through (12), final bulk 
retentate (13), final filtered Melan-A (14). Samples were analyzed under reducing conditions. 
Primary antibody was used at a 1/20,000 dilution. Melan-A monomer appears at 14 kDa.   
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ICH quality guidelines on the production of biotechnological products calls for testing to ensure 
stability of the active components in the final container 
184
. The product can be sensitive to a 
variety of environmental conditions including but not limited to temperature, shear, and light. 
Therefore, a 500 µl aliquot of final filtered Melan-A was aliquoted into a glass vial or plastic 
cryovial for primary and secondary stability testing. Primary stability testing calls for samples to 
be analyzed 1 day, 1 week, 1 month, 2 months, and 3 months at 4 ºC, -20 ºC, and -80 ºC. 
Secondary testing required samples be analyzed 1 day, 1 week, and 1 month into storage at the 
following conditions:  4 ºC inverted/right side up, Room temperature inverted/ right side up, 37 
ºC right side up, UV exposed for -80 ºC/4 ºC, Extended vortexing (20 min) for -80 ºC/4 ºC, and 
freeze-thaw at -80ºC to RT. After one day no discernible effects of temperature were recorded. 
At one week in storage, primary stability showed normal consistency while secondary stability 
showed some discoloration in the samples stored at 37 ºC. The vortexed samples showed some 
protein precipitation but no degradation. Figure 2.7a&b shows a coomassie stained SDS-PAGE 
and Anti-His western blot of the secondary stability test samples after 1 month. The samples 
exhibited fair stability after one month with the exception of the samples stored at 37 ºC which 
was expected under the accelerated degradation condition. A fair amount of degradation can be 
seen in the SDS-PAGE gel correlating to a reduce intensity of the Melan-A monomer band in the 
western blot of the 37 ºC sample. Under refrigerated and frozen storage our product is clear, 
colorless, and absent of visible particulate and can be reliably stored in glass or plastic vials. 
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Figure 2.7 a) Coomassie stained SDS-PAGE gel of secondary stability test samples. Lane assignments are 
protein ladder (1), RT-glass (2), RT-cryovial (3), 37 ºC-glass (4) 37 ºC cryovial, (5), 4 ºC-glass-UV (6), 4 
ºC-cryovial-UV (7), -80 ºC-glass-UV (8), -80 ºC-cryovial-UV (9), 4 ºC-glass-vortex (10), 4 ºC-cryovial-
vortex (11), -80 ºC-glass-vortex (12), -80 ºC-cryovial-vortex (13), -80 ºC-glass-freeze/thaw (14), -80 ºC-
cryovial-freeze/thaw (15). b) Anti-Histidine western blot of secondary stability test samples. Lane 
assignments are as follows: protein ladder (1), RT-glass (2), RT-cryovial (3), 37 ºC-glass (4) 37 ºC 
cryovial, (5), 4 ºC-glass-UV (6), 4 ºC-cryovial-UV (7), -80 ºC-glass-UV (8), -80 ºC-cryovial-UV (9), 4 
ºC-glass-vortex (10), 4 ºC-cryovial-vortex (11), -80 ºC-glass-vortex (12), -80 ºC-cryovial-vortex (13), -80 
ºC-glass-freeze/thaw (14), -80 ºC-cryovial-freeze/thaw (15). Samples were analyzed under reducing 
conditions. Primary antibody was used at a 1/20,000 dilution.  
 
CONCLUSION 
GMP pilot scale production of Melan-A showed similar challenges to those seen in our previous 
report on NY-ESO-1 
162
. Melan-A is highly insoluble in aqueous solution and requires the 
presence of high concentrations of urea to stay in solution. Melan-A also has a strong affinity for 
endotoxin and like NY-ESO-1 requires a detergent wash step during IMAC purification to 
significantly reduce endotoxin levels before downstream purification 
189
. The modifications to 
purification process from our previous report on NY-ESO-1, specifically a chromatographic 
anion exchange step and flow through cation column, resulted in higher yields per fermentation 
for Melan-A. Yields can be further improved with careful section of filtering units in 
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downstream processing.  Endotoxin and Residual DNA levels in the final bulk product were well 
below the specified limit for a recommended 330 µg dose. Our final yield was 11.1 grams of 
protein from one twenty liter fermentation with a purity level of 91% as determined by mass 
spectrometry. This material meets the standards for use in phase 1 clinical trials.        
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Chapter 3: Aptasensor Based on Polymer-Gold Nanoparticles Composite Microspheres for the 
Detection of Malathion Using Surface-Enhanced Raman Spectroscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted with permission from “Aptasensor Based on Polymer-Gold Nanoparticles Composite 
Microspheres for the Detection of Malathion Using Surface-Enhanced Raman Spectroscopy” 
Industrial Biotechnology (2013)  
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ABSTRACT 
In this paper, we present a new format of apta-sensing composite particles for Surface-Enhanced 
Raman Spectroscopy (SERS) detection of malathion. The developed apta-sensing microspheres 
comprise extraction capability by aptamer-target analyte interaction and Raman signal enhancer 
for SERS detection of the pesticide.  
Micron-sized polymer particles were synthesized by polymerization by precipitation using 
methacrylic acid (MAA) and ethylene glycol dimethacrylate (EGDMA) as co-monomers in 
acetonitrile. Conjugation with colloidal gold nanoparticles (AuNPs) via modification with 2-
aminoethanethiol led to polymer-AuNP composites with controlled aggregation of AuNPs onto 
the polymer surface. The thiolated aptamer targeting malathion was attached to the metal surface 
by thiol-gold interaction, resulting in polymer-AuNP-aptamer composite microspheres. The new 
material was characterized by imaging using Scanning Electron Microscopy (SEM) and 
Dynamic Light Scattering (DLS) measurements. The polymer-AuNP-aptamer particles were 
incubated with a phosphate buffer solution containing malathion at a suitable concentration level 
for 30 min, washed with water and then dried on a microscope glass slide, prior to spectra 
acquisition. The proposed apta-sensing SERS substrate successfully allows the direct detection 
of the target molecule at 3.3 µg mL-1. Because of only basic equipment is required for analyte 
separation, the apta-sensing microspheres are well suited for potential industrial applications that 
require on-site analyte detection. 
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INTRODUCTION 
In the 1970s it was first reported that the Raman signal intensity of molecules could be 
dramatically increased by chemi-adsorption onto a roughened noble metal surface. 
46, 48
 Since 
then, interest of researchers has grown in Surface-Enhanced Raman Spectroscopy (SERS) and 
SERS-based technologies. In recent years, the detection of small molecules, peptides, proteins or 
DNA, has been addressed using SERS, resulting in an increasing number of publications. Some 
features of SERS make it a particularly versatile and effective technique for sensing in 
bioanalytical 
59, 194
 and homeland security 
91
 applications, such as its high sensitivity, molecular 
fingerprinting ability, multiplex capability, minimal background signal from water, and the speed 
and cost effectiveness compared to standard procedures. Moreover, the electromagnetic 
enhancement mechanism of SERS can create localized surface plasmons (LSP) from the 
matching of the resonance frequency of the valance electrons of a noble metal with the frequency 
of the incident light that can further enhance the Raman signal of the target 
52
.  
Malathion is the most common organophosphate insecticide applied in the United States, 
195
 used 
primarily in agriculture and domestic use for eradication and control of pests. The structure of 
malathion is shown in figure 1. Presently, there is no definitive information showing effects of 
chronic toxicity of malathion 
195
 and due to its low toxicity to humans 
196
 it is considered safe to 
use. However, because of its widespread use, it is necessary to develop detection methods to 
monitor the presence of malathion in different environmental compartments (eg. surface waters, 
soil, etc.). Analytical methodologies for malathion, together with other organophosphorous 
pesticides have recently been developed through gas chromatography-mass spectrometry (GC-
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MS), 
197-199
 gas chromatography-nitrogen phosphorus detector (GS-NPD) 
200-202
 or  high 
performance liquid chromatography-diode array detector (HPLC-DAD), 
203, 204
 among others. 
These methods successfully analyzed the target analyte with satisfactory limits of detection. 
However, these types of procedures often involve time and labor intensive sample preparation, 
and separation prior to the final detection, 
205
  taking up to 80% of total time spent on analysis. 
205, 206
 
SERS-based sensors can be classified into two categories: intrinsic and extrinsic sensors. With 
intrinsic (or direct) sensing, the molecular fingerprint of the target analyte is acquired directly. 
This method has been applied to wide variety of small biological molecules 
59
 and microfluidic 
devices for detection of dyes. 
207
  Extrinsic sensors employ SERS-active nanotags consisting of 
distinguishable SERS-active reporters or molecules with unique spectral fingerprints, for indirect 
measurements of the analyte of interest. Some extrinsic systems have been developed for small 
molecule detection including Au NPs functionalized with a 16 amino acid peptide selective to 
protective antigen (PA) coupled with the Raman reporter molecule 5,5′-dithiobis(succinimidyl-2-
nitrobenzoate) to detect PA for anthrax screening 
208
 or displacement of rhodamine 6G by 
glutathione on nanoparticles for reverse detection in aqueous solution. 
209
   
In order to provide molecular affinity to SERS sensors toward the aim of improving reliability, 
the use of cyclodextrin inclusion complexes (CICs) or molecularly imprinted polymers (MIPs) 
for direct detection of analytes has been reported. 
210, 211
  An alternative strategy to chemical 
modifications for molecular recognition is to use DNA aptamers which can bind to selected 
targets with high affinity. Aptamers present unique advantages over chemical modifications: 
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from well-established screening protocols to versatility in modifications for labeling and surface 
chemistry. Use of aptamers in SERS sensors has been reported for extrinsic detection of cocaine 
by analyzing the conformational changes to the aptamers upon binding the target analyte. 
95, 212
 
For this purpose it is necessary to obtain a reliable and highly reproducible DNA signal, which 
can be a limitation on the development of this class of methods. In this study we exploit the 
specificity of DNA aptamer recognition capability with the simplicity of intrinsic analyte 
detection by demonstrating a method of direct detection of malathion using DNA apta-SERS 
substrates.           
EXPERIMENTAL 
Materials 
Ethylene glycol dimethacrylate (EGDMA), methacrylic acid (MAA), 2-aminoethanethiol, N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC), azobisisobutyronitrile 
(AIBN), tetrachloroauric (III) acid, sodium citrate, 2-(N-morpholino) ethanesulfonic acid (MES) 
were obtained from Sigma-Aldrich (MO, US); (3-aminopropyl)triethoxisilane (APTES) and 
analytical grade malathion were purchased from Fluka (Buchs, Switzerland). EGDMA and MAA 
were freed of inhibitors prior to use using a disposable, pre-packed column (22.5 x 2.0 cm), 
obtained from Aldrich.  AIBN was recrystallized from methanol prior to use. All the organic 
solvents were at least HPLC grade and purchased from Sigma-Aldrich. All other chemicals were 
used as received. Ag-coated SERS Diagnosis Membranes were kindly supplied by iFyber (SER-
DM
TM
, iFyber LLC, Ithaca, NY, US). 
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Preparation of SERS substrates 
Synthesis of gold nanoparticles 
Colloidal gold nanoparticles (AuNP) were prepared by reduction of chlorauric acid with sodium 
citrate, according to a methodology adapted from Frens. 
66
 In brief, 50 mL of a HAuCl4 (1mM) 
aqueous solution were heated to boil and a fixed amount of sodium citrate solution (1%) was 
then added. The reaction mixture was cooled after 20 min of boil. The concentration of AuNPs in 
the resulting solution was determined by absorbance measurements (λ=520nm) using a 
Nanodrop ND-1000 spectrophotometer (Thermo Scientific; Rockford, IL) and molar extinction 
coeffiecients for AuNPs derived from Yguerabide et al. 
213
 
Preparation of glass-gold nanoparticle substrates 
Glass bottom microwell dishes with an uncoated coverslip (P35G-14-C, MatTek Corporation, 
Ashland, MA, US) were cleaned with nitric acid, thoroughly rinsed with deionized water and 
dried under nitrogen flow. Then, 100 µL of aqueous 5 mM APTES were deposited on the glass 
surface. After 15 minutes, the substrates were again rinsed with deionized water and dried under 
nitrogen. Subsequently, 100 µL of colloidal gold solution were located on the modified glass and 
allowed to dry. The glass-gold substrates were finally rinsed with DI water and dried prior to use.  
Synthesis of polymer microspheres 
Cross-linked polymer microspheres were prepared by precipitation polymerization. Purified 
MAA (0.46 mmoles, 39.4 µL), EGDMA (2.32 mmoles, 453.2 µL) and initiator AIBN (0.2 
mmoles, 33 mg) were mixed with 20 mL of acetonitrile and placed in a glass vial fitted with a 
screw-cap which served as reaction vessel. The mixture was degassed by a gentle N2 stream for 
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10 min. The bottle was sealed and introduced into a temperature controllable incubator equipped 
with a Spindrive orbital shaker platform (Bel-Art, Wayne, NJ, US) powered by a standard 
magnetic stirrer that allowed slow agitation of the solution during the course of the 
polymerisation. The temperature was maintained at 60 ºC for 20 h. The polymer microspheres 
formed were separated from the reaction medium by vacuum filtration on a Magna nylon 
membrane filter with 0.45 µm of pore size (Osmonics, Minnentoka, MN, US)   and then 
sequentially washed with acetonitrile. 
Preparation of Polymer-Gold nanoparticle composite microspheres 
Polymer microspheres were functionalized taking advantage of the presence of available 
carboxyl groups from the MAA. An amount of 0.2 g of polymer microspheres was dissolved in 
15 mL of MES buffer at pH 5.5 and mixed with 200 mg of EDC previously dissolved in 5 mL of 
water. The mixture was stirred during 30 min and 75 mg of 2-aminoethanethiol (cysteamine) in 2 
mL of water were added. The suspension was kept under stirring for 3 hours after which the 
polymer-cys functionalized particles were filtered, washed with water and resuspended in 5 mL 
of water. An aliquot of 1 mL of this suspension was added to 10 mL of AuNP solution under 
stirring, leading to the formation of polymer-AuNP composite microspheres. 
DNA aptamer development 
The aptamer targeting malathion was developed using the modified Systematic Evolution of 
Ligands by EXponential enrichment (SELEX) method of Bruno et al. 
214
 Briefly, analytical 
grade malathion from Fluka was immobilized on a PharmaLink affinity column (Thermo 
Scientific; Rockford, IL) per instructions detailed by the manufacturer. The column was 
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incubated with the SELEX DNA library and the bound DNA was eluted and amplified by 
polymerase chain reaction (PCR). The PCR product was used for six subsequent rounds of 
SELEX. The aptamer designated as M17 Forward (M17-F) 
215
 was purchased from Integrated 
DNA Technologies, Inc. (IDT; Coralville, IA) with the following sequence: 5’-ThioMC6-
ATCCGTCACACCTGCTCT-TATACACAATTGTTTTTCTCTTAACTTCTTGACTGC-
TGGTGTTGGCTCCCGTAT-3’.  Aptamer structure is schematically depicted in Figure 3.1C.  
The aptamer contained a thiol C-6 modifier on the 5’ end for conjugation to gold nanoparticles 
attached to the surface of the polymer microspheres. The secondary structure and sequence are 
shown in figure 3.1 C. A stock solution was made by reconstituting the aptamer to 100 µM in 
nuclease free water. The stock was stored at -20 ºC for further use. 
Preparation of polymer-AuNP-aptamer conjugates  
Polymer-AuNP particles functionalized with DNA-aptamers on the surface were prepared 
according to the methodology developed by Taton et al. 
216
 The equation mol conjugated 
aptamer=An×Cn×Do×V (eq. I) was used to calculate the amount of aptamer to attach to the 
polymer-AuNP particle; where An is the surface area of the microsphere, cn is the concentration 
of the original AuNP solution (particles L
-1
), Do is the aptamer density on the particle (35 pmol 
cm
-2
), and V is the volume of the reaction (L).  A mole excess (1.5 times ) of the amount of 
aptamer calculated with equation 1 (~10 µL) was then added to 500 µL polymer-AuNP particles 
suspension and rotated on a rocking table at 1 Hz  in the exclusion of light for 16 h. Next, 0.250 
vol of 1M NaCl/0.1 M sodium phosphate buffer (buffer I) was added and the particles were 
rotated for an additional 4 hours. The conjugated particles were centrifuged at 3000 rpm for 4 
min to remove excess aptamer and were resuspended in 500 µL of 0.1 M NaCl/10 mM sodium 
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phosphate buffer (buffer II). The particles were centrifuged and resuspended two more times and 
finally resuspended in 125 µL of buffer II.  
Characterization techniques 
Dynamic Light Scattering measurements 
The sizes of AuNP, the polymer microspheres and the polymer-AuNP-aptamer conjugates were 
analyzed through dynamic light scattering (DLS). Suspensions of the three different types of 
particles were prepared using water as dispersant and transferred to 400 µL disposable sizing 
cuvettes, measuring the diffusion of the particles moving under Brownian motion using a 
Zetasizer Nano-ZS (Malvern Instruments Ltd, Worcestershire, UK). 
Scanning Electron Microscope Imaging 
Scanning Electron Microscope (SEM) was used to characterize the polymer-AuNP. The images 
were obtained using a LEO 1550 FESEM (Keck SEM). The dried particles were first coated with 
an electrically conductive gold-palladium coating approximately 10 nm thick and then placed on 
a silicon wafer for imaging. The resolution at 5 KeV was 2.5nm. 
SERS Measurements 
SERS spectra were obtained using a Renishaw InVia Confocal Microscope system (Renishaw 
Inc; Hoffman Estates, IL) equipped with a 785 nm edge laser and Renishaw CCD Camera 
(Renishaw Inc; Hoffman Estates, IL) fitted to a Leica microscope. The spectra for polymer-
AuNP-aptamer and glass-Au-aptamer substrates were taken with a 50x objective at an exposure 
time of 10s and a laser power of 1%. The ~1.0 µm laser spot was focused on a single particle on 
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the surface. All spectra were obtained using a 785 nm excitation. The spectra were analyzed 
using GRAMS AI spectroscopy suite (Thermo Scientific; Rockford, IL). 
Glass-gold substrates 
To the glass-gold substrates a 10 µL aliquot of 1 µM thiolated aptamer solution in buffer I was 
added and incubated at 4ºC overnight. The substrates were rinsed with DI water and dried before 
SERS measurements. In the same manner, glass-gold substrates were incubated with a 1 mM 
(330 µg mL
-1
) solution of malathion in ethanol for 24 h. 
SERS Diagnosis Membrane 
The membranes were cut into small squares (0.5x0.5 cm size) and incubated with 1mM (330 µg 
mL
-1
) solution of malathion in ethanol for 24 hours. The membranes were then rinsed with DI 
water and placed onto a glass slide for SERS measurements. 
Glass-gold-aptamer-malathion experiments 
For the glass-gold-aptamer-malathion experiments, 100 µL aliquot of 3 nM thiolated aptamer 
solution in buffer I was incubated on the glass-gold substrate at 4ºC for 24 hours. After this 
incubation time, 100 µL aliquot of malathion in buffer II was added. After 15 min, the substrates 
were thoroughly rinsed with DI water, allowed to dry and SERS spectra were finally obtained. 
Polymer-AuNP-aptamer-malathion binding experiments 
The polymer-AuNP-aptamer particles were aliquoted (125 µL in buffer II) and incubated with 
the same volume of a solution of buffer II containing malathion at a suitable concentration level 
for 30 min. After this time, the particles were centrifuged, separated from the supernatant and 
washed with an equal volume of DI water three times. Finally, a volume of 100 µL was allowed 
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to dry on a microscope glass slide, previously cleaned with nitric acid, prior to spectra 
acquisition.       
RESULTS AND DISCUSSION 
We propose a new composite material based on polymer-AuNP-aptamer sensing particles 
capable of acting as capture and signal-enhancer for SERS detection of malathion (Figure 3.1A). 
A schematic representation of this composite materal is shown in Figure 3.1 A. Fabrication of 
multimeric SERS substrates is better suited than the methods based on aggregation of gold 
nanoparticles through changes in the electrostatic charge, which can affect reproducibility. In 
order to obtain reference SERS spectra of the analyte malathion, we used Ag-coated SERS 
diagnosis membranes as a positive control substrate. For the same purpose, SERS substrates of 
AuNPs aggregated on the surface of APTES-coated glass slides were prepared to obtain a 
reference SERS signal of each component of our multimeric system. 
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Figure 3.1 A) Illustration demonstrating preparation of polymer-AuNP-aptamer subtrates for 
SERS detection of malathion. B) Chemical structure of malathion. C) Sequence and predicted 
secondary structure of DNA aptamer M17-F used to bind malathion. 
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Preparation and characterization of polymer-AuNP-aptamer substrates 
Polymer-AuNP microspheres 
When designing our composite SERS substrate, different parameters such as the morphology of 
the polymer support, as well as the type, size and organization of the AuNP, were taken into 
account. In this work, we have adapted the methodology proposed by Prasad et al. 
217
 to form 
polymer-AuNP composites with controlled aggregation of AuNPs onto the polymer surface. 
Dyanamic light scattering (DLS) analysis of the synthesized AuNPs indicated a size of ~ 40 nm 
with a Gaussian distribution shown in figure 3.2C.  
Studies have shown that whereas the signal resulting from measurements obtained using 
colloidal nanoparticles is highly dependent of the number of nanoparticles in the laser beam, the 
variation in signal using microsphere-AuNP composite substrates is independent of the number 
of microspheres in the sample. 
218
 We decided to use as support polymer microspheres with a 
diameter size comparable with the focal volume of the laser, so that each Raman measurement is 
restricted to a single microsphere surface.  Figure 3.2A shows an image taken with the 
microscope coupled to the Raman spectrometer with a single bead (center of picture) illuminated 
by the laser. For practical considerations, particles in the range of µm size are also easier to 
handle and can be subjected to routine processes such as centrifugation or filtration, preserving 
its performance. Additionally, it was important to minimize the porosity of the polymer beads in 
order to restrict the distribution of AuNP onto the surface of the microspheres. The polymer 
microspheres should show a suitable chemical functionality to allow for subsequent preparation 
of polymer-AuNP composite particles. Polymer microspheres were prepared by polymerization 
by precipitation using MAA and EGDMA as co-monomers and acetonitrile as porogen. 
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Acetonitrile permits formation of particles with a low level of porosity, and MAA provides 
carboxyl groups on the surface for the conjugation with AuNP via modification with 2-
aminoethanethiol. It was important to obtain a narrow size distribution which may affect the 
quality of the Raman signal. In our case, based on prior knowledge in our laboratory, the 
polymerization was conducted directly with 2.5% monomer concentration and produced 
monodispersed polymer particles of an appropriate size (diameter of 1.6 µm), with no obvious 
signs of aggregation and a narrow size distribution obtained by DLS measurements displayed in 
figure 3.2D.  
Figure 3.2B is a SEM image of the surface of a composite particle prepared as described in the 
experimental section, based on the methodology proposed by Prasad et al. 
217
. AuNPs can be 
seen distributed throughout the polymer surface either in a monodispersed manner or forming 
small aggregates. Although beyond the scope of the work, it was found that the addition of 
smaller amounts of AuNP provided poorer coverings, whereas the addition of a greater amount 
of gold caused the formation of independent gold clusters. It is of note that there were no signs of 
irreversible aggregation of polymer-AuNP composite particles over several months. Although 
the particles sedimented after approximately two hours in suspension, it was possible to 
resuspend them easily by vortex. This provides an additional advantage of the proposed 
composite material, compared to the instability of the AuNPs by themselves, which is one of its 
main limitations. 
219
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Figure 3.2. A) Light microscope images of polymer-AuNP-aptamer substrates immobilized on 
glass surface. B) Representative SEM image of polymer-AuNP-aptamer substrates. The inset 
illustrates clustering of 40 nm gold nanoparticles on surface of polymer substrate. (C-E) 
Histogram showing the size distribution of Au-NPs, Polymer microspheres, and Polymer-AuNP-
Aptamer subtrates respectively as measured by Dynamic Light Scattering. 
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Polymer-AuNP-aptamer conjugates  
The conjugation of the aptamers to the polymer-AuNP particles was carried out following a 
methodology adapted from Taton et al. 
216
 The maximum number of units of oligonucleotide per 
nanoparticle is limited, and it depends on the area of the nanoparticles and the sequence and 
length of the aptamer. 
220
 The amount of aptamer used in the conjugation was calculated 
according to equation I considering the entire polymer microsphere as a gold particle. After 
functionalization with aptamer, the particles remained in suspension without settling to the 
bottom of the vial for longer than polymer-AuNP particles, suggesting an effective surface 
coverage with aptamer. Figure 3.2E shows the size distribution of the polymer-AuNP-aptamer 
particles obtained by dynamic light scattering. It can be observed that the composite 
microspheres retained their morphology after the conjugation with AuNPs and aptamers and only 
a small excess of gold appears in the histogram.  
In order to distinguish between the background signal of DNA and the signal characteristic of the 
target analyte, SERS measurements were conducted using with previously reported substrates. 
Figure 3.3 shows the SERS spectra obtained using glass-gold substrates prepared as described in 
the experimental section, after incubation with different amounts of aptamer thiol-C6-M17-F. 
Although the obtained signal appears in a region of the spectrum where the signal of citrate has 
been reported, 
218, 221
 the increase in the intensity of the signal by increasing the amount of DNA 
immobilized on the substrate indicates that the observed signal between ~ 800 cm
-1
 and ~ 1800 
cm
-1
 corresponds to the DNA. Similarly, bands corresponding to DNA can be observed in the 
same region of the spectra for our polymer-AuNP-aptamer system, as shown in figure 3.4. This 
result is consistent with previous studies reporting SERS detection of DNA. 
222
 According to that 
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work, it is possible to obtain a highly reproducible signal of DNA, by applying an appropriate 
thermal treatment. This kind of process is required for indirect measurements, where the 
molecule bound to the aptamer is detected via a target-induced conformation change. 
95, 223, 224
 
However, direct sensing of malathion can be carried out using our polymer-AuNPs-aptamer 
system in a suitable solution without any previous thermal treatment by directly measuring 
characteristic peaks of the target analyte. 
 
Figure 3.3. SERS spectra taken on glass SERS substrate conjugated with 1 µM or 3 nM 
concentration of aptamer M17-F modified with a 5’ thiol group containing a six carbon spacer.  
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Sensing experiments for malathion 
Although the electromagnetic enhancement mechanism does not require the analyte to be in 
direct contact with the SERS substrate, for best enhancement the distance between the analyte 
and the metal surface should be in the range of a 0.01 to 10 nm. 
52
 In order to perform direct 
measurements of the analyte, the polymer-AuNPs-aptamer system can operate as an extractant of 
the pesticide from the solution by specific interaction between the aptamers and the analyte for 
which they were designed. Conformational changes produced by the rearrangement in the 
presence of target analyte allow the molecule to be in close proximity to the metal surface. Given 
that Raman measurements were made with the samples dried on a glass slide, the aptamers 
exhibited different conformations on the surface of the particles, resulting in variability in the 
DNA signal. However, operating in a suitable concentration range, characteristic peaks of 
malathion were clearly observed in every measurement, indicating that the aptamer-analyte 
interaction was preserved in the vicinity of the surface. Figure 3.5B shows the SERS spectra of 
polymer-AuNP-aptamer particles incubated as described in the experimental section with a 16.5 
µg mL
-1
 (20 µM) solution of pesticide, together with the spectra obtained using SERS Diagnosis 
Membrane, as reference substrate (Figure 3.5A).  . Multiple matches can be observed in the 
wavenumbers of the peaks assigned to malathion, (eg 500 cm
-1
, 527 cm
-1
, 714 cm
-1
) in a region 
of the spectra free of DNA signal, enabling the direct detection of the pesticide. These peaks 
assigned to malathion were not present in the spectra obtained from blank samples (Figure 3.4A). 
Finally, we selected the peak at ~ 495 cm
-1
 which was better defined and provided a greater 
sensitivity. As shown in Figure 3.6, such a peak (~ 497 cm
-1
) is also present in the spectra 
obtained after incubation of the pesticide with the reference glass-gold substrates functionalized 
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with thiolated aptamer on the surface. According to previous data, 495 cm
-1
 can be assigned to P-
S stretching mode 
225
 of malathion. 
 
Figure 3.4 Comparison of: A) SERS spectra of 330 µg mL
-1 
 malathion in ethanol incubated 24 h 
on iFyber™ SERS Diagnostic Membrane and B) SERS spectra of 16.5 µg mL-1 malathion in 
buffer solution incubated 30 min with polymer-AuNPs-aptamer substrates.  Spectra are offset for 
clarity.  
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Figure 3.5 SERS spectra of: A) polymer-AuNPs-aptamer substrate incubated with a blank buffer 
solution; B) polymer-AuNPs-aptamer substrate incubated with a 16.5 µg mL
-1 
malathion in 
buffer solution. Incubation time was 30 min. Spectra are offset for clarity and characteristic 
peaks for malathion are highlighted. 
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Figure 3.6 SERS spectra of glass SERS substrate incubated with 330 µg mL
-1 
malathion in 
ethanol for 24 h (grey); and SERS spectra of glass SERS substrate-aptamer (blue) incubated with 
6.6 µg mL
-1 
malathion in buffer for 30 min.  
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It is of note that malathion could not be detected with the polymer-AuNP microspheres lacking 
modification with the aptamer following washing with DI water. The washing step was able to 
remove all material nonspecifically adsorbed onto the surface during the 30 min incubation 
period. This suggests that the modification of the polymer-AuNP beads with the aptamer 
promotes binding of the pesticide by specific interaction with the aptamer.  
Analytical performance and application 
The apta-sensing system for malathion was applied to pesticide solutions at different 
concentration levels. Selectivity for the target molecule in a sample which would also likely 
contain potential interfering molecules may be an issue. In this sense, experiments with tap water 
spiked with malathion have been also carried out. The ionic content usually present in tap water 
is also a challenge for the operation of our system.   
Limits of detection 
The theoretical limits of detection calculated as three times the average signal of the background 
noise obtained in the analysis of six blank samples 
226
 were 0.3 and 0.75 µg mL
-1 
for standard 
solutions and spiked tap water solutions, respectively. However, in practice such a value is in a 
concentration range where the variability in the signal is very high. Consequently, an 
experimental limit of detection of 3.3 µg mL
-1 
was estimated considering the smallest 
concentration of analyte in the test sample that was reliably distinguished from zero according to 
the judgment of the researchers (Figure 3.7). This experimental LOD is comparable with the 
value provided by other studies that address the direct SERS detection of malathion
227
.  
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Figure 3.7 Comparison of SERS detection of malathion using 495 cm
-1
 peak with polymer-
AuNPs-apt substrates at: A) 16.5 µg mL
-1 
of malathion; B) 3.3 µg mL
-1 
of malathion; C) blank 
buffer solution. Spectra are offset for clarity.    
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Linearity  
It is important to stress that the poor solubility of malathion in aqueous solution (145 µg mL
-1
, 
log Pow 2.75) 
228
 is the primary limiting fact of the apta-sensor for this specific pesticide. Above a 
concentration level of 33.3 µg mL
-1
, it is possible to observe the formation of a film of malathion 
which prevents focus of the laser on the sample resulting in no Raman signal. Taking these facts 
into account, the range of application can be reliably restricted to one order of magnitude and 
thus, the polymer-AuNP-aptamer successfully allows the detection of the target molecule in a 
concentration range between 3.3 µg mL
-1
 and 33.3 µg mL
-1
. Linearity was checked with fortiﬁed 
tap water samples and good correlation was observed in the range of  concentration  studied, 
with r=0.998. 
Precision  
The repeatability was studied in terms of the relative standard deviation (RSD) of the values of 
concentration found obtained at different spiking levels in tap water samples. Table 1 shows the 
expected and calculated concentrations of malathion with their respective RSDs values. 
Although the value of RSD for concentration levels close to the estimated limit of detection is 
25%, for a higher level of concentration (16.5 µg mL
-1
) the RSD drops to acceptable levels of 
14%. 
CONCLUSIONS 
In this paper, we present a new format of apta-sensing composite particles for SERS detection of 
malathion. The developed polymer-AuNP-aptamer microspheres combine extraction capability 
by aptamer-target analyte interaction and Raman signal enhancer for SERS detection of the 
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pesticide. Working under described experimental conditions, the polymer-AuNP-aptamer 
successfully allows the direct detection of malathion at 3.3 µg mL
-1
, which compares well other 
SERS substrates reported. 
227
 The apta-sensing microspheres are a system well suited for 
industrial and agricultural applications as only basic equipment is required for analyte separation. 
As hand held and bench-scale Raman spectroscopy systems become more powerful, apta-sensing 
microspheres can become a reliable method for on-site pesticide detection.   
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Chapter 4: Synthesis and Characterization of doxorubicin molecularly imprinted polymers for 
sustained release drug delivery system 
 
INTRODUCTION 
In the past 50 years the pharmaceutical industry has explored a variety of techniques to 
incorporate drugs into polymers. A majority of the polymer systems employed by the industry 
are either cellulose derivatives, micelle forming polymers, or acrylamide derivatives 
229
. In most 
polymeric drug delivery systems (DDS) an inert polymer is loaded with a compound which is 
released via burst, controlled, or pulsatile delivery. The pharmacokinetic properties of the 
bioactive agents are often greatly enhanced in polymer DDS through increased plasma half-life 
and protection from enzymatic degradation that leads to dosage reduction for patients 
230, 231
. 
Combined with the potential for active targeting, polymer DDS field is a rapidly growing field 
for anti-cancer drug therapeutics, which often have a variety of well documented side-effects
232
.  
The most common carriers for drug therapeutics are N-(2-hydroxypropyl)-methacrylamide 
(HPMA) copolymer drug conjugates. Polymer-drug conjugates are advantageous over 
systemically administered drug through limit of drug uptake to endocytosis, increase in the 
circulation time of the drug, and accumulation of drug in the leaky vasculature of tumors
231
. 
Several HPMA polymer conjugates for the anthracyline doxorubicin have been reported in the 
literature 
233-237
.  
In addition to polymer-drug conjugates, an emerging field in polymer drug delivery systems is 
molecular imprinting of polymers for drug delivery. Molecularly imprinted polymers (MIPs) are 
polymer networks with specific recognition sites for a target molecule 
238
. Molecularly imprinted 
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polymers have been used to a wide extent in the field of analytical chemistry in liquid 
chromatography
239-242
, solid-phase extraction
243-246
, biomimetic sensors
247-249
, and catalysts
250
. 
MIPs work by providing shape specific cavities for a template with exposed functional groups 
inside the cavity to form multiple stable interactions with the template
122
. This feature provides 
specific recognition for a molecule or family of molecules that are complementary in shape and 
functionality to the template used in the preparation which can be exploited for drug delivery. 
The interactions can be specific enough as to even allow for the enantioseparation of 
molecules
251-255
. The template can be removed by disruption of the specific interactions between 
the monomers and template and specific empty cavities can be reloaded with an established dose 
of therapeutic drug. As opposed to polymer conjugate systems, MIPs do not require local 
degradation of the polymer to release drug
256
. MIPs can act as a stable reservoir for drug and 
decelerate the rate of drug release in a given media
129, 257
 and characteristics such as particle size, 
porosity, and monomer interactions can be used to control the release of drug.  If the therapeutic 
window of the drug is narrow the MIP can keep the concentration of the drug below toxicity 
level but above the minimum effective dose
258
. The highly cross-linked MIP polymer networks 
are also resistant to degradation and a variety of stimuli (pH, temperature, irradiation, electric 
current) can be used to control the release of therapeutic drug into the local environment
105
. In 
summary, MIPs are cheap, versatile, rationally designed materials with tailor-made properties 
that make them suitable for drug delivery. In this work we describe the production of nanometer 
range MIP particles for doxorubicin from methacrylic acid (MAA), 4-vinylpyridine (4-VP), and 
ethylene glycol dimethacrylate (EGDMA).       
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EXPERIMENTAL 
Materials 
Methacrylic acid (MAA), ethylene glycol dimethacrylate (EGDMA), 4-Vinylpyridine (4-VP), 
and azobisisobutyronitrile (AIBN), were obtained from Sigma-Aldrich (MO, US); Doxorubicin 
(DOX) was obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). EGDMA, MAA, 
and 4-VP were freed of inhibitors prior to use using a disposable, pre-packed column (22.5 x 2.0 
cm), obtained from Aldrich.  AIBN was recrystallized from methanol prior to use. All the 
organic solvents were at least HPLC grade and purchased from Sigma-Aldrich. All other 
chemicals were used as received. 
Preparation of polymer substrates 
Synthesis of polymer microspheres 
Cross-linked non-imprinted and imprinted polymer nanospheres were prepared by 
polymerization by precipitation. Doxorubicin imprinted polymers were synthesized by first 
dissolving 5 mg of doxorubicin into 1 mL of acetonitrile/toluene solution by sonication. Once 
dissolved, 4-VP (69.0 µmoles, 7.444 µL) and MAA (69.0 µmoles, 5.85 µL) were added to the 
mixture and allowed to incubate for 10 minutes.  EGDMA (0.69 mmoles, 136 µL) was added 
after the incubation step and the mixture was brought up to a final volume of 12 mL with 
acetonitrile/toluene solution (25% toluene v/v). 60.7 µmoles, 10 mg of the initiator AIBN was 
dissolved into the MIP solution and the mixture was degassed by a gentle N2 stream for 10 min. 
A glass vial fitted with a screw-cap served as the reaction vessel. The vial was sealed and placed 
into a temperature controllable incubator equipped with a Spindrive orbital shaker platform (Bel-
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Art, Wayne, NJ, US) powered by a standard magnetic stirrer that allowed slow agitation of the 
solution during the course of the polymerisation. The temperature was maintained at 60 ºC for 20 
h. The polymer nanospheres that were formed were separated from the reaction medium by 
vacuum filtration on a Magna nylon membrane filter with 0.1 µm of pore size (Osmonics, 
Minnentoka, MN) and then washed with acetonitrile to remove excess monomer and initiator. 
Entrapped doxorubicin was extracted from MIPs by 5 extractions in 25 mL of methanol/acetic 
acid (2.5% v/v) until there was no detectable levels of doxorubicin in the extract. The particles 
were then washed a final time in acetonitrile and allowed to dry. Non-imprinted polymer was 
prepared following the same protocol in the absence of template.  
Characterization 
Dynamic Light Scattering measurements 
The size of the polymer nanospheres was analyzed through dynamic light scattering (DLS). 
Dilute suspensions of the different types of particles were prepared using water as dispersant and 
transferred to 400 µL disposable sizing cuvettes, measuring the diffusion of the particles moving 
under Brownian motion using a Zetasizer Nano-ZS (Malvern Instruments Ltd, Worcestershire, 
UK). 
Scanning Electron Microscope Imaging 
Scanning Electron Microscope (SEM) was used to characterize the polymer particles. The 
images were obtained using a LEO 1550 FESEM (Keck SEM). The dried particles were first 
coated with an electrically conductive gold-palladium coating approximately 10 nm thick and 
then placed on a silicon wafer for imaging. The resolution at 5 KeV was 2.5nm. 
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Fourier Transform - Infrared Spectroscopy (FT-IR) 
FTIR spectra for the polymer particles were generated using a Bruker Optics - Vertex80v FTIR 
spectrophotometer equipped with a diamond ATR crystal accessory for analysis of bulk samples. 
FTIR spectra were acquired between 450-7000cm
-1
. Particles were washed thoroughly before 
analysis as stated previously.   
Polymer Evaluation 
Fluorescence Evaluation of Polymers 
Imprinted and non-imprinted polymer particles (10 mg) were incubated in 1.5 mL of 1 µg/mL, 
10 µg/mL, 25 µg/mL, 50 µg/mL, and 66 µg/mL solutions of doxorubicin in acetonitrile for 12 
hours. After the incubation, the samples were centrifuged at 9,000x g for 6 minutes and the 
supernatant was collected. The particles were washed with 500 µL of acetonitrile to remove 
loosely associated template. The template was extracted from the polymer matrix in two steps by 
re-suspending the particles in 1 mL of methanol/acetic acid (2.5% v/v) and samples were 
sonicated for 25 minutes at 50 ºC. The particles were centrifuged and the extract collected. 
Analysis of each extraction was performed using a LS50B luminescence spectrometer (Perkin 
Elmer; Waltham, MA) with a low volume special optical glass cuvette. The samples were 
excited at λ = 479 nm and the emission spectrum of the solution were collected and analyzed. 
The peak height at λ = 549 nm was chosen for quantification based on emission maxima from 
standard curves and studies by Karukstis et al.
259
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Polymer-Doxorubicin Release Kinetics  
Dried polymer (20 mg) samples were incubated in 1, 10, 25, and 50 µg/mL solutions of 1.5 mL 
of doxorubicin in acetonitrile for 12 hours. The particles were subsequently centrifuged, the 
supernatant discarded, and the excess of solvent was removed to produce a dry powder.  
The drug loaded polymers were then suspended in 2 ml of water and transferred to SnakeSkin
®
 
Pleated dialysis tubing (MWCO 10,000, flat width 34 mm, diameter 22 mm, volume/length 3.7 
ml cm
-1
, Thermo Scientific; Rockford, IL). The tubing was sealed and transferred to a capped 
100 ml Pyrex
®
 flask containing 14 ml of water. The dissociation of doxorubicin was determined 
by spectroscopic analysis of the water (ex: λ479 nm; em: λ558 nm) at specified time intervals. 
Aliquots were returned to the samples after analysis.    
 
RESULTS AND DISCUSSION 
Polymer preparation and characterization 
The macromolecular specificity of MIPs stems from the formation of cavities inside the 
polymers that are complementary to the shape of the template, and functional groups around the 
template that form multiple stabilizing interactions 
105
. When choosing the interaction type, 
whether covalent or non-covalent imprinting, the type of drug delivery system to be explored and 
the release mechanism need to be considered 
111
. For most drug delivery systems, non-covalent 
interactions are favored as it allows for drug release to reach the minimum effective 
concentration without exceeding the therapeutic window of the drug through controlled release 
mechanism 
258
. 
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Figure 4.1 Representation of hypothetical prepolymerization complex with doxorubicin, 
methacrylic acid (MAA) and 4-vinylpyridine (4-VP). Combinations of functional monomer units 
are used to increase binding capacity of MIPs compared to polymers formed from a single 
monomer. The basic functional monomer 4-VP can provide hydrogen bonding through the lone 
pair electrons on the nitrogen atom in the pyridine ring as well as hydrophobic interactions. 
 
The ratio of template to functional monomer units is one major factor in developing precise 
interactions for non-covalent molecular imprinting
111
. Too much functional monomer promotes 
non-specific interactions because its favors the formation of randomly distributed functional 
monomers throughout the polymer network that can non-specifically interact with the analyte. 
Too little functional monomer leads to weak specific interactions. Additionally, MIPs need to 
restrict the non-specific interactions in aqueous solutions as MIPs could potentially absorb small 
proteins and lipids on the polymer surface 
105
. Finally, the polymers need to have a high degree 
of water solubility to be used as drug delivery systems. While much work has been done in the 
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field of imprinting in aqueous media, the strong interaction of water with the template often 
curtails the interactions of the monomer units thereby reducing specificity and binding capacity 
260
.  Through precipitation polymerization in organic solvents; whereas the polymer forms it 
becomes immiscible with the solvent and precipitates out of solution, it is possible to produce 
water soluble imprinted particles.  In this work, molecularly imprinted polymers were 
synthesized for doxorubicin by varying types of monomer units, molar ratio of template to 
monomer units, and the final weight percent of monomer in polymerization reaction to produce 
MIPs with a strong affinity for doxorubicin. After careful selection of solvent which plays a 
critical role in template recognition and overall porosity of the particles
261, 262
, doxorubicin MIP 
and non-imprinted polymer particles were prepared first by examining the effect of the types of 
monomers on water stability and imprinting effect. As doxorubicin contains a large aromatic 
region, 4-vinylpyridine was chosen as one of the co-monomer units for the template due to its 
potential to promote π-π stacking and hydrophobic interactions with the template with some 
electrostatic interactions. The polymers were prepared by polymerization by precipitation using 
4-VP with EGDMA was the cross linker in acetonitrile/toluene mixture (3:1, v/v) to a molar ratio 
of 0.5:8:40 of doxorubicin to 4-vinylpyridine/EGDMA (1.5 wt %).  The large ratio of monomer 
units was chosen to create a enough stable interactions for the doxorubicin which would prevent 
leakage of the drug since the ratio of template to functional monomer units is one major factor in 
developing precise interactions for non-covalent molecular imprinting
111
. Investigation into the 
optimal solvent for polymerization was limited by the low solubility of doxorubicin in several 
organic solvents. A mixture of acetonitrile/toluene (3:1, v/v) permitted the formation of particles 
with an intermediate level of porosity with toluene potentially promoting imprinting effects in 
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the polymer between the dox and 4-VP. In order to examine the morphology of the NIP and MIP 
under these conditions, a comparison of the SEM images of the polymerization products for the 
NIP and MIP are illustrated in Figure 4.2A & B. Under these conditions the particles exhibit a 
high level of aggregation in water and resemble more of a bulk polymer than isolated particles as 
shown in the images. The particles were loaded with a 50 µg/ml dox solution in acetonitrile, 
toluene, or water for 12 hours and extracted with MeOH/AcOH mixture. Analysis of the 
fluorescence of the extract showed no evidence of imprinting effect when imprinted polymers 
were compared to the control (data not shown). Any isolated particles were also 1-5 µm in 
diameter which is beyond the desired threshold. Other monomer formulations included using 
divinylbenzene (DVB) as a cross linker along with MAA and 4-VP to form a more stable cavity 
for the doxorubicin via a combination of hydrogen bonding and π-π interactions as previously 
explored in the work of Ye et al with MIPs for inhibitors of kallikrein
263, 264
. However, particles 
made with DVB were as expected highly insoluble in aqueous media and tended to readily form 
aggregates despite numerous warm sonications.   
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Figure 4.2. Representative SEM images of (a) non-imprinted 1.5 wt% 4-vinylpyridine/ethylene 
glycol dimethacrylate polymer particles (b) 1.5 wt% imprinted 4-vinylpyridine/ethylene glycol 
dimethacrylate polymer particles (c) 1.25 wt% non-imprinted methacrylic acid/4-
vinylpyridine/ethylene glycol dimethacrylate polymer particles (d) 1.25 wt% imprinted 
methacrylic acid/4-vinylpyridine/ethylene glycol dimethacrylate polymer particles.  
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In order to improve the imprinting performance of the particles, MAA was added as a co-
monomer unit to a final molar ratio of 0.5:4:4:40 of dox to MAA, 4-VP, and EGDMA. 
Methacrylic acid can potentially create a more stable pre-polymerization complex with the 
template since it is smaller and less rigid than 4-VP and does not promote non-specific 
interactions as does the pyridine group. Use of MAA has been cited in many studies 
257, 265, 266
 
and it is suitable for compounds with optimal stability a lower pH
267
, such as doxorubicin. The 
monomer weight percent was also reduced 1.25% in an attempt to decrease particle size. The 
particles formed using MAA/4-VP as functional monomers and EGDMA as cross linker are 
shown in the SEM images in figure 4.2C & D. The images show that the addition of MAA 
provided particles with a more uniform morphology than those obtained only with 4-VP (figure 
4.2A & B) and with less visible differences in polymer morphology between NIP and MIP. The 
effect of decreasing the monomer concentration is seen in the controlled size of the particles as 
measured by dynamic light scattering (figure 4.3). The non-imprinted and doxorubicin imprinted 
particles obtained with the polymerization mixture containing MAA/4-VP/EGDMA had an 
average diameter of less than 400 nm with small differences between MIP and NIP.  
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Figure 4.3 Dynamic light scattering (DLS) particle characterization of methacrylic acid, 4 
vinylpyridine, and ethylene glycol demethacrylate imprinted and non-imprinted polymers (A) 
Comparison of particles size distribution for MAA/4-VP/EGDMA non-imprinted (NIP) and 
imprinted (MIP) polymers. (B) Average peak diameter of NIP and MIP.  
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Figure 4.4 FTIR spectra of MAA/4-VP/EGDMA non-imprinted (black) and imprinted polymer 
(blue). The particles contained 1.25 wt% functional monomer polymerized in a 3:1 (v/v) mixture 
of acetonitrile and toluene.   
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The FTIR spectra of unloaded NIP and MIP are shown in figure 4.4. In the FTIR spectra for the 
NIP and MIP the medium peak at 2950.9 cm
-1
 and the peak at 1382.8 cm
-1
correspond to C-CH3 
bending from the methyl groups of the MAA and EGDMA. The peak at 1724.2 cm
-1
 is a typical 
vibration of a conjugated C=O stretching vibration contributed by the MAA with some 
contribution from the ester bonds found in EGDMA. The peaks at 1040 and 1242 cm
-1
 are 
assigned to aromatic C-H bending of the pyridine group. The strong peak at 1448.4 is indicative 
of an aromatic ring stretch also contributed by the 4-VP. 
268
    
Evaluation of Adsorption Capacity 
Evaluation of the adsorption capacity of the MIP to doxorubicin is critical to determining the 
performance of the MIP and its capability to be used as a drug delivery system. The imprinted 
polymer should have higher retention of the template when compared to the control polymer 
across a range of concentrations. Doxorubicin MIP and non-imprinted polymer particles were 
evaluated by measuring the fluorescence signal of the extracts obtained according to the 
procedure described in the experimental section. 10 mg of MIP and NIP particles incubated with 
varying amounts of doxorubicin (0.15 – 10 µg/mg polymer). The particles were centrifuged to 
remove unbound drug that remains in the supernatant. Particles were then washed with 500 µL 
of acetonitrile, centrifuged and drug bound specifically was finally extracted in a mixture of 
methanol/acetic acid and the amount of doxorubicin recovered in the extract was determined by 
monitoring the fluorescence at 549 nm. The washing step with acetonitrile helps remove any 
non-specifically bound template or template concentrated in non-specific binding sites. Each set 
of particles underwent a second extraction step to determine whether any sorbed template 
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remained in the polymer after the initial extraction. In comparing the adsorption capacity of the 
particles, there is a marked increase in selectivity for the template over the range of loading 
concentrations in the doxorubicin imprinted polymer particles (figure 4.5). The differences in the 
amount extracted between MIP and NIP can be seen in the loading supernatant and wash for the 
imprinted polymer which was visually clear compared to the control. The washing supernatant of 
the NIP had a significant level of drug indicating solvation of drug from non-specific or large 
binding sites. The amount of drug extracted in each stage was also consistent with a strong 
imprinting effect. After the first extraction, the MIP and NIP particles underwent a second 
extraction in methanol/acetic acid. Table 4.1 details the extraction levels for five different 
loading concentrations from two subsequent extraction steps. It can be observed that the amount 
of doxorubicin extracted in the second stage is greater for the MIP, which clearly indicates 
stronger specific interactions between the molecule of interest and the polymer taking place in 
the specific cavities. The precise loading and dose control capability of MIPs   
Table 4.1 The amount of drug (µg) extracted in two successive extractions with a mixture of 
methanol/acetic acid (2.5% AcOH v/v). The extraction mixture was analyzed by fluorescence at 
549 nm. The samples were taken in triplicate and mean with standard deviations reported.  
 NIP MIP 
Concentration Extraction 1 Extraction 2 Extraction 1 Extraction 2 
1 µg/mL 0.89 ± 0.027 0.24 ± 0.025 1.01 ± 0.015 0.43 ± 0.018 
10 µg/mL 7.77 ± 0.02 0.95 ± 0.012 10.5 ± 0.054 1.79 ± 0.018 
25 µg/mL 18.1 ± 0.043 3.09 ± 0.014 26.2 ± 0.057  9.91 ± 0.027 
50 µg/mL 29.7 ± 0.125 5.62 ± 0.047 33.9 ± 0.035 13.6 ± 0.063 
66 µg/mL 19.9 ± 0.10 2.41 ± 0.036 33.1 ± 0.09 9.08 ± 0.029 
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Figure 4.5 Plot of adsorption isotherm of NIP (□) and MIP (◊) loaded with doxorubicin measured 
by fluorescence at 549 nm. The difference in extracted doxorubicin between MIP and NIP 
reaches a maximum at a loading of 75 µg doxorubicin.   
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Evaluation of Imprinting Effect 
To further characterize the recognition properties of the material, the extraction data was fit to 
the Langmuir isotherm model that describes a theoretical saturation value for adsorption of 
molecules into a surface with a discrete number of binding sites. The adsorption constant (k) and 
binding site density (N) were calculated by the Langmuir model expressed as:  
  
   
    
 
where B is the amount of adsorbed template and C is the concentration of unbound template in 
solution respectively. N and k are the Langmuir constants for binding site density/adsorption 
capacity and adsorption constant. The Langmuir isotherm is derived based on the assumption (a) 
adsorption does not exceed beyond monolayer coverage (b) all surface binding sites are equal 
and can be occupied by only one template which occurs if the pre-polymerization complex is 
good (template-functional monomers) (c) the binding of template is not affected by the presence 
of template in a neighboring site that occurs if the prepolymerization complex, and subsequently 
the specific cavities, are distributed homogeneously along the polymeric network. The value of 
the isotherm constants were calculated by graphing 1/B versus 1/C where the slope of the 
intercept/slope corresponds to adsorption constant and 1/intercept to the binding site density. The 
imprinted polymer shows a higher maximum amount of sorbed species as well as a five-fold 
increase in the adsorption equilibrium constant. The correlation coefficients (R
2
) suggest that the 
Langmuir model gives a satisfactory fit over the concentration range in the study that suggests 
that the polymer addresses the premises of the Langmuir model: discrete number of specific 
 99 
 
binding sites that are homogenously distributed. The extended version of the Langmuir model 
was also used to evaluate the adsorption data but fits did not give adequate correlation over the 
entire range (table 4.2) for both polymer preparations.   
Table 4.2   Apparent adsorption constant and binding site density for the adsorption of 
doxorubicin onto MIP and NIP 
 Parameter R
2
 R
2 
(extended) 
MIP N = 37.17 
k = 0.392 
 
0.993 0.986 
NIP N = 26.38 
k = 0.069 
0.998 0.859 
 
Final application of the particles as drug delivery system requires a well characterized system, 
and prediction of the adsoption and release kinetics in a suitable media. The release kinetics of 
doxorubicin from the imprinted polymer was evaluated. Imprinted polymer particles were loaded 
with various amounts of doxorubicin (3.75-0.075 µg dox/mg polymer), dried, and placed in 
dialysis tubing. The extent of release of doxorubicin in water at 37 ºC was measured by taking 
aliquots at several time points and monitoring the increase in fluorescence at 558 nm. A slow 
release of doxorubicin was observed over the 26 hour time scale (figure 4.6). The release profile 
for each concentration is indicative of deviation from Fickian release behavior of particles 
samples with size distribution when compared to monodispersed samples
269
. Particles below the 
mean size distribution tend to accelerate the release of drug during the early stages while 
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particles above the mean suppress the release curve at later time points.
269
 This is seen in the 
rapid release of doxorubicin in the first six hours with a leveling of release in the latter 20 hours.   
Characterization of the release characteristics of doxorubicin from the molecularly imprinted 
polymer was done using the Peppa equation
232, 269
 for non-swellable spheres:  
  
  
     
where Bt is the amount of drug released at time t and B∞ is the amount of drug released at 
equilibrium. The k constant represents the apparent release rate and n the diffusion exponent. 
This model can be applied to describe the kinetics of the adsorption release in order to 
characterize the MIP as a drug delivery system. A plot of ln(Mt/Mo) vs. ln(t) under the highest 
loading conditions is shown in figure 4.7. The effect of particle distribution of the samples is 
seen in the calculated diffusion exponent which is below the theoretical limit for Fickian 
diffusion (n=0.43) as the value of n is strongly affected by the size and shape of the distribution 
curve for polydispersed samples.
269
 However the drug release profile of drug from the polymer is 
indicative of controlled release behavior and this confirms the utility of our particles as a drug 
delivery system.  
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Figure 4.6 Profile of controlled release behavior of molecularly imprinted polymer for loadings 
of 0.075 µg dox/mg polymer (black), 0.75 µg dox/mg polymer (red), 1.87 µg dox/mg polymer 
(blue), and 3.75 µg dox/mg polymer (green).    
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Figure 4.7 (A) ln(Mt/M∞) versus ln(t) plot for molecularly imprinted polymer loaded with 3.75 
µg dox/mg polymer (B) Diffusion exponent calculated from ln(Mt/M∞) versus ln(t) plot of each 
loading concentration for doxorubicin-loaded polymers in water at 37 ºC 
 
CONCLUSION 
In the study we have demonstrated the synthesis and characterization of doxorubicin molecularly 
imprinted polymers via precipitation polymerization. The MIPs have a higher adsorption 
capacity than the control polymer which increases with each extraction indicating a high degree 
of specific binding sites within the polymer. Furthermore the release kinetics of the polymer 
particles in water are indicative of a diffusion based controlled release mechanism. The 
dissociation of the doxorubicin from the polymer can be improved by decreasing the 
concentration of cross linker in the polymerization mixture which produces to more flexible 
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cavities. The carboxyl groups on the surface of the polymer can be used for further modification 
for targeting or photo-responsive imprinted polymers. 
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Chapter 5: Synthesis and Characterization of Silica-Au-Molecularly Imprinted Polymer SERS 
Substrate for Detection of Thiabendazole 
 
INTRODUCTION 
Rapid and accurate monitoring of environmental or biological samples for contaminants for food 
supply protection to bio-warfare is an important topic in the sensing field
59, 91
. Chemical and 
biological sensors are gaining increased prominence in the field as of signal transductions 
become more sophisticated. Chemical and biological sensors typically classified by the method 
of signal transduction which can be optical, electric, electrochemical, mass sensitive, magnetic, 
or thermometric
270
. Biological sensors also take advantage of biological macromolecules with 
specific recognition for ligands to impart a high level of specificity to the system. However, there 
is a need to develop analytical techniques that are capable of detecting a particular analyte 
without the aid of a secondary label. In the case of biological sensors, many of the biological 
macromolecules, such as antibodies or receptors, are particularly sensitive to media composition 
and storage conditions. This can limited their ability to be integrated into truly field portable 
devices.  
Molecularly imprinted polymers (MIPs), synthetic polymers with specific recognition sites to a 
target analyte within the material scaffold, have the potential to overcome these challenges.  
MIPs are normally prepared by copolymerizing a functional monomer(s) with a crosslinker in 
the presence of a template molecule in solution. After polymerization, the template is removed 
from the polymeric network revealing cavities with specific molecular recognition properties. 
The advantages of MIPs, compared to receptors of biological origin, include greater mechanical 
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and thermal stability, as well as very low cost of preparation 
113
. These advantages enable MIPs 
to function under a wide range of operating conditions, making the technique of molecular 
imprinting a very useful tool in many analytical fields, such as extraction techniques, chemical 
separation techniques and chemical sensing. These materials are also simple to prepare, scalable, 
and can be integrate into a variety of platform like microfluidics. MIPs have been used in a 
variety of formats and detection applications over the past two decades 
271
.  
Surface Enhanced Raman Spectroscopy (SERS) can be used to tackle the issue of field 
portability and signal transduction. Surface Enhance Raman is a form of Raman spectroscopy 
where the transitions between vibrational states are studied when a molecule in-elastically 
scatters light. The technique is highly sensitive with enhancement factor of at least 10
6 
and single 
molecule detection has been reported
52, 55, 272-276
. The power of this technique lies in the 
multiplex capability as the Raman spectra has far less spectral overlap compared to fluorescence. 
SERS substrates have also been used with commercially available hand held devices with parts 
per trillion level detection limits
218
. It is therefore possible to merge the specific capture and 
retention capability to a MIP with the sensitive analytical capacity of SERS to make a truly field 
portable, rapid, and specific sensor. For a successful integration of both techniques, the distance 
between the molecule to be measured and the metal nanoparticles responsible for signal 
amplification is of great importance. For best signal enhancement, the molecule to be measured 
needs to be in close vicinity to the metal colloids. There are successful attempts combining both 
approaches, such as gold nanoparticles embedded in a layer of MIP prepared by emulsion 
polymerization
210
. However, this approach does not guarantee a precise control of polymer 
particle size in the nanometer range. Furthermore, since SERS is a phenomenon restricted to the 
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surface, is convenient to use techniques that allow polymerization on surface controlling the 
thickness of the MIP layer. Thus, diffusion and access of the target molecule to the polymer 
matrix is easier and the analyte can be recognized by the MIP in proximity to the metal colloid. 
In this regard, polymerization via-iniferter (initiator, transfer agent, terminator) is a suitable 
approach that permits precise control of the thickness of a layer of polymer prepared from a 
surface area where the initiator is coupled by varying the UV exposure time 
277
. The main 
advantage of using iniferter-type initiators (eg dithiocarbamates) instead of conventional azo-
based initiators, resides in its radical products. Iniferters generate two free radicals, one of which 
is active and coupled to the surface; another free radical that is inactive and stable in solution but 
capable of terminating the growing polymer chains by recombination. In this manner, 
polymerization occurs only via the active radical immobilized onto the support surface, and 
polymerization in solution is avoided. 
In this work we report the development of a prototype SERS-MIP composite microparticles 
based on the principle of living free radical polymerization of the MIP from the surface of a 
novel SERS substrate for adsorption and detection of thiabendazole (TBZ), a widely used 
benzimidazole fungicide.  
EXPERIMENTAL 
Materials 
Phenyltrimethoxysilane (PTMS), methyltrimethoxysilane (MTMS), (3-Aminopropyl) 
trimethoxysilane (APTMS), (3-Aminopropyl) triethoxysilane (APTES) ethylene glycol 
dimethacrylate (EGDMA), and methacrylic acid (MAA), thiabendazole (TBZ), tetrachloroauric 
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(III) acid, sodium citrate, 2-(N-morpholino) ethanesulfonic acid (MES), and sodium 
diethyldithiocarbamate trihydrate were obtained from Sigma Aldrich. (p-Chloromethyl) 
phenyltrimethoxysilane (CBTMS) was purchased from Gelest. HPLC grade toluene, 
tetrahydrofuran (THF), and acetonitrile (ACN) were at least HPLC grade from Sigma Aldrich. 
All other chemicals were used as received.     
Methods 
Synthesis of gold nanoparticles 
Colloidal gold nanoparticles (AuNP) were prepared by reduction of chlorauric acid with sodium 
citrate, according to a methodology adapted from Frens. 
66
 In brief, 50 mL of a HAuCl4 (1mM) 
aqueous solution were heated to boil and a fixed amount of sodium citrate solution (1%) was 
then added. The reaction mixture was cooled after 20 min of boil. The concentration of AuNPs in 
the resulting solution was determined by absorbance measurements (λ=520nm) using a 
Nanodrop ND-1000 spectrophotometer (Thermo Scientific; Rockford, IL) and molar extinction 
coeffiecients for AuNPs derived from Yguerabide et al. 
213
 
Synthesis of organically modified core shell silica microspheres 
Silica microspheres containing a hydrophobic core with a hydrophilic shell were prepared 
according to a modification of the procedure described by Koo et al 
278
. To form the core, 62 mL 
of deionized water and 76 µL of HNO3 was heated to 60 ºC in a 100 mL round bottom flask in a 
water bath on a hot plate stirrer.  Once the temperature of the reaction mixture reached 60 ºC, 
707.8 µL (3.72 mmol) of PTMS was added to the flask and the mixture was vigorously stirred 
for 30 seconds. After which, 15 mL of NH4OH was added to the flask. The solution was kept 
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stirring for an additional hour until the solution turned a milky white.  The shell was prepared by 
separately combining 262.7 µL (1.5 mmol), of APTMS, 330 µL (1.5 mmol) of CBTMS, and 
641.25 µL (4.5 mmol) of MTMS in a glass vial and adding the mixture to the flask all at once. 
The suspension was kept stirring for 75 minutes. The resulting particles were vacuum filtered 
through  a 0.45 µm pore size Magna nylon membrane filter (Osmonics, Minnentoka, MN). The 
microspheres were washed three times with water and then resuspended in 1:2 mixture of 
water/ethanol and sonicated. The particles were filtered a second time in the same manner and 
allowed to air dry.  
Iniferter Modification of Silica microparticles 
250 mg of silica microparticles were resuspended in 2 mL of THF. The suspension was kept 
stirring while 1 mL of a solution of sodium diethyldithiocarbamate (10 mg/mL) was added 
dropwise to the suspension. The suspension was stirred for 3 hours and then vacuum filtered 
through a 0.45 µm pore size Magna nylon membrane filter (Osmonics, Minnentoka, MN) and 
washed three times with THF. The particles were allowed to air dry overnight.  
Preparation of Silica-Gold composite microspheres 
200 mg of iniferter modified silica microparticles were suspended in 5 mL of deionized water. 5 
mL of Au-NPs were added to the suspension in 1 mL aliquots. The particles were stirred for 1 
hour and excess Au-Nps were removed by centrifugation at 1,500 x g in a microcentrifuge. The 
particles were resuspended in THF centrifuged a second time. The particle pellets were air dried 
overnight.    
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Grafting of MIP on Iniferter modified Silica Microparticles 
200 mg of iniferter modified silica was suspended in 2 mL of a MIP polymerization mixture 
containing 11.7 mg of TBZ (1 mmol), 40 mg of MAA (8 mmol) and 460 mg of EGDMA (40 
mmol) in 6.25 mL of toluene. The suspension was purged with argon for ten minutes and then 
the glass vial was tightly sealed. The polymerization was carried out using UV-irradiation at 4 ºC 
with a Spectroline EB-280C UV lamp (Westbury, NY). The vials were placed on top of an 
orbital shaker 5 cm from the lamp. After 10 hours of irradiation the Si-MIP particles were 
centrifuged to remove polymerization mix. The particles were resuspended in toluene and 
centrifuged to remove the solvent. The template was extracted from the Si-MIP for SERS 
measurements by four warm sonication baths at 50 ºC using a  mixture of acetonitrile/acetic acid 
(1:1, v/v). The nonimprinted polymer (Si-NIP) was prepared in the same fashion but without the 
addition of thiabendazole.   
Characterization 
Dynamic Light Scattering measurements 
The size of the microspheres was analyzed through dynamic light scattering (DLS). Dilute 
suspensions of the different particles were prepared using water as dispersant and transferred to 
400 µL disposable sizing cuvettes, measuring the diffusion of the particles moving under 
Brownian motion using a Zetasizer Nano-ZS (Malvern Instruments Ltd, Worcestershire, UK). 
Scanning Electron Microscope Imaging 
Scanning Electron Microscope (SEM) was used to characterize the microparticles. The images 
were obtained using a LEO 1550 FESEM (Keck SEM). The dried particles were first coated with 
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an electrically conductive gold-palladium coating approximately 10 nm thick and then placed on 
a silicon wafer for imaging. The resolution at 5 KeV was 2.5nm. 
Fourier Transform - Infrared Spectroscopy (FT-IR) 
FTIR spectra for the pesticide loaded microparticles were generated using a Bruker Optics - 
Vertex80v FTIR spectrophotometer equipped with a diamond ATR crystal accessory for analysis 
of bulk samples. FTIR spectra were acquired between 450-7000cm
-1
.  
SERS Measurements 
30 mg of Si-NIP and Si-MIP were incubated overnight in 1.5 mL of TBZ solution in toluene to a 
final concentration of 100 µM. The particles were centrifuged and resuspended in 300 µL of 
water. Glass microscope slides were cleaned with nitric acid, thoroughly rinsed with DI water 
and dried under argon flow. 100 µL of 5 mM APTES solution was deposited on the glass surface 
for 15 min. The substrates were then rinsed with DI water and dried under argon. A 100 µL 
aliquot of the Si-NIP and Si-MIP suspension were placed on the APTES modified glass slide and 
air dried. SERS spectra were obtained using a Renishaw InVia Confocal Microscope system 
(Renishaw Inc; Hoffman Estates, IL) equipped with a 785 nm edge laser and Renishaw CCD 
Camera (Renishaw Inc; Hoffman Estates, IL) fitted to a Leica microscope. 
RESULTS AND DISCUSSION  
Formation of core shell silica nanoparticles 
In this work we are presenting the preparation of silica-Au-MIP (Si-Au-MIP) composite SERS 
substrates for detection of thiabendazole. Figure 5.1A details a schematic of the design process 
for the composite SERS substrate. The support of the substrate is a silica-based microparticle 
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decorated with functional amine and phenyl methyl chloride groups. The silica support was 
designed to have two functionalities. The first function was to serve an initiator surface for 
polymerization of the MIP layer by grafting from the silica particles 
279, 280
 taking advantage of 
this well characterized polymerization chemistry. Its second function is to act as SERS substrate 
enhancing the Raman signature of the target molecule selectively recognized by the MIP layer. 
For this purpose, gold nanoparticles are attached to the surface of the silica support, before 
grafting with the MIP layer. 
When designing the Si-Au-MIP composite we must take into account the need for the analyte to 
be in close proximity to the SERS substrate. While other SERS substrates rely on non-specific 
binding/interaction of the analyte on the surface, our MIPs can selectively bind and at the same 
time bring the analyte in close proximity to the surface of the SERS substrate. As only the 
analyte of interest is trapped close to the SERS substrate, the system proposed here avoids the 
occurance of background signal of undesired compounds potentially present in the samples, 
providing added selectivity and sensitivity to the measurements. Thus, this composite material 
simultaneously acts as both an extracting agent and detection system.  
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Figure 5.1 (a) Schematic representation of Si-Au-MIP preparation. Process begins with 
preparation of a hydrophobic phenyltrimethoxysilane (PTMS) core. A hydrophilic shell of 
methyltrimethoxysilane (MTMS), (3-Aminopropyl) trimethoxysilane (APTMS), and (p-
Chloromethyl) phenyltrimethoxysilane (CBTMS) was formed around the core. Sodium 
diethyldithiocarbamate trihydrate reacts with the CBTMES to form the iniferter modified 
surface. 40 nm Au-NPs attach to the surface via interaction with the amine groups from APTMS. 
Polymer synthesis is initiated from the surface of the particle through UV formation of iniferter 
radicals (b) Chemical structure of thiabendazole 
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Core-shell silica microspheres were synthesized in a two-step synthesis process using the 
precursors, PTMS, MTMS, APTES, and CBTMS. Initially, 3.72 mmol of PTMS was hydrolyzed 
in a dilute solution of nitric acid. The silane monomers were then condensed under basic 
conditions by adding 15 mL of NH4OH and the solution was stirred for an additional hour to 
form the hydrophobic core. The size of the particle core can be adjusted by either reducing the 
concentration of PTMS or increasing the duration of hydrolysis. We designed the synthesis of  
particle cores that are approximately 1 µm in diameter by using a high concentration of PTMS 
and a short hydrolysis time. We desired each Raman measurement to be restricted to an 
individual microsphere surface as studies have shown that variation in signal using microsphere-
AuNP composite substrates is independent of the number of microspheres in the sample. 
218
  
The microspheres cores were capped with a mixture of APTMS, MTMS, and (p-chloromethyl) 
phenyl –trimethoxysilane (CBTMS). The capping mixture was added to the PTMS core 
suspension and stirred for 75 minutes. The comparatively more hydrophilic shell of MTMS 
imparts an increased level of solubility to the microparticles in aqueous solutions. The amine 
functionality provided by the APTMS is used for formation of microsphere composites with an 
external layer of gold nanoparticles. The halogenated silane CBTMS, provides functionality for 
modification of the surface with the dithiocarbamate iniferter molecule for later MIP 
polymerization. Figure 5.2 shows an SEM image of the unmodified silica microparticles. The 
core-shell microparticles show no visible signs of aggregation and have a narrow size 
distribution.  
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Figure 5.2 Representative SEM image of core-shell silica microparticles prepared with a core 
layer of trimethoxyphenylsilane (PTMS) and a shell layer consisting of trimethoxymethylsilane 
(MTMS), (3-aminopropyl)trimethoxysilane (APTES), and (p-chloromethyl) phenyl-
trimethoxysilane (CBTMS).    
 
After modification of the surface with the dithiocarbamate iniferter, the particles showed no 
visible differences in morphology (figure 5.3A) The average size of the particles is 
approximately 1.3 µm which is comparable with the focal volume of the laser (figure 5.3B). The 
core-shell silica microparticles were then coated with a layer of gold nanoparticles. A SEM 
image of the composite microparticles is shown in figure 5.3C. The gold attaches to the surface 
with some clustering. However, the particles are still well distributed across the entire surface 
forming multiple junctions for potential SERS “hot-spots”. The particles also maintained their 
morphology and did not aggregate in solution. The average size of the particles increased slightly 
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(figure 5.3D) which was expected after attaching the gold nanoparticles onto the surface via 
interactions with amine groups. 
 
Figure 5.3 (a) Representative SEM image of iniferter modified microspheres. (b) Histogram of 
number percent size distribution of iniferter modified particles measured using dynamic light 
scattering. (c) SEM image of Si-Au composite particles after coating with 40 nm gold 
nanoparticles. (d) Histogram of size distribution of Si-Au composite microparticles.  
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FTIR characterization of core-shell particle synthesis 
An evaluation of the surface modifications during each step of the synthesis of the microsphere 
composite was carried out using FTIR. The core-shell microparticles showed several 
characteristic peaks as illustrated in figure 5.4. The peaks between 700-800 cm
-1
 can be assigned 
to the aliphatic chloro group of CBTMS. The strong band at 1000-1100 cm
-1
 corresponds to the 
organic siloxane groups contained in all of the monomers. The peak at 1429 cm
-1
 is assigned to 
the methyl C-H asymmetric/symmetric bend contributed by the CBTMS. The small peak at 1591 
cm
-1
 is from the primary amine group on the APTES.  
After reaction with the dithiocarbamate group, the FTIR spectra of the iniferter-modified core-
shell silica microparticles were compared to the base core-shell particles (figure 5.4). Several 
distinct peaks were seen in the iniferter-modified particles that did not appear in the unmodified 
particles. The most obvious distinction is a strong band at 2900-3000 cm
-1
, assigned to the 
methyl asymmetric/symmetric stretch from the iniferter terminal methyl groups. Another strong 
peak appears at 1770-1720 cm
-1
 which can be assigned to the carbamate ester in the iniferter.  
The iniferter modified core-shell particles still had a strong band for the chlorine of the CBTMS 
which indicates incomplete reaction of the surface.        
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Figure 5.4 FTIR spectra of core-shell particles (black) and iniferter-modified core-shell particles 
(blue). Characteristic peak of methyl groups contributed by sodium diethyldithiocarbamate 
trihydrate are seen at 2900 cm
-1
.  
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Characterization of Molecularly Imprinted polymers  
A MIP for TBZ was polymerized from the surface of the core-shell iniferter modified particles 
for 12 hours at 4 ºC by UV radiation. This kind of MIPs has been polymerized from the surface 
of core-shell particles in literature
279, 280
. However, there is a lack of studies reporting this type of 
polymerization in systems with the presence of gold nanoparticles, which presumably could have 
an impact in the following MIP grafting. In our work, despite the presence of gold nanoparticles 
on the surface of the modified silica beads, the polymerization via-iniferter was carried out 
successfully from those regions in the core-particles still exposed to the UV radiation. The 
particles were subsequently analyzed by SEM to determine if the polymer did form on the 
surface of the particle. Figure 5.5A shows an SEM image of an extended network of polymer 
around individual and groups of particles of some thickness for the Si-Au-MIP composites. The 
relative thickness of the polymer was difficult to analyze as the polymerization resulted in cross 
reaction of polymer into aggregates. The particles were analyzed by dynamic light scattering 
(figure 5.5B) which showed an average particle size of approximately 3.5 µm in diameter. 
However this figure can be attributed to a measure of the aggregate size and not of an individual 
microparticle thickness.   
 119 
 
 
Figure 5.5 (a) SEM image of iniferter modified Si-Au composite microparticles with molecularly 
imprinted polymer of thiabendazole grown from the surface. Imprinted polymer was made from 
MAA and EGDMA at a ratio of template to monomers 1:8:40 in toluene. (b) Average diameter 
of microparticles at different stages in the preparation as analyzed by dynamic light scattering.   
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The FTIR spectra of the core-shell composites microparticles and the core-shell-MIP 
microparticles are shown in figure 5.6. There is a marked difference in the spectra which can be 
attributed to the mechanism of iniferter directed formation of polymer. As the iniferter 
polymerizes it can also act as a terminator of the polymer chains. Therefore the MIP surface 
should be decorated with terminating carbamates. Confirmation that this polymer was indeed 
polymerized from the surface via the iniferter is the strong band at 2900 cm
-1
 that corresponds to 
the methyl groups of the iniferter. Interestingly this peak does not appear in the Au coated 
composite particles. Other peaks can be assigned to MAA and EGDMA, in particular the strong 
peak at 1700 cm-1 is assigned to the carboxyl group of the methacrylic acid. The peak at 1380 
cm
-1 
is assigned to the C-CH3 bending vibrations of the methyl groups of MAA, EGDMA, and 
dithiocarbamate.  The strong peaks between 950 cm
-1
 and 1225 cm
-1
 are contributed by the 
thiabendazole aromatic C-H in plane bends.  
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Figure 5.6 FTIR spectra of Si-Au composite particles (blue) and Si-Au-MIP composites (black). 
The characteristic peak of the iniferter termination is seen at 2900 cm
-1
. A strong peak for the 
carboxyl group of MAA is seen at 1700 cm
-1
. 
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SERS detection of thiabendazole  
To test the Si-MIP composite particles ability to act as a SERS substrate, the template was first 
extract and then Si-NIP and Si-MIP composite particles were reloaded with 100 µM solution of 
thiabenzadole in toluene overnight. The particles were washed and analyzed for SERS activity. 
Reloading of the particles with template in organic media promotes hydrogen bonding 
interactions in the specific cavities. Depending on the solvent used for reloading we can clarify 
the origin of the differences in binding specificity between MIP and NIP.  Figure 5.7 illustrates 
the signal generated from the Si-Au-MIP and Si-Au-NIP particles under 10% laser power. Of 
note is that despite the thick layer, the analyte was capable to access to the specific binding sites 
in the MIP network, permitting the interaction with the plasmons occurred on the metal colloid 
surface, allowing thus the desired SERS effect. Our developed Si-Au-MIP particles had a 
characteristic peak at 1279 cm
-1
 which can be attributed to selective detection of TBZ by our 
system 
281
. The peak at 1279 cm
-1
 as well as the bands at 1580 and 1452 cm
-1
 can be attributed to 
ring stretching vibrations
281-283
. These peaks are not present in the spectra obtained under the 
same conditions with the Si-Au-NIP system. Both spectra share a peak at 1000 cm
-1
 that most 
likely is the dithiocarbamate SERS signal, as the thiol groups can interact with the gold on the 
surface of the particle. This fact clearly suggests an effective imprinting that permitted to the 
analyte to access to the proximity of the gold nanoparticles by permeability through the polymer 
network establishing specific analyte-polymer interactions. However, the formation of 
aggregates and clusters of the composite material can have the effect of potentially difficult the 
access of analyte to the surface of the metal. An improved adjustment of the polymerization time 
can overcome this issue. We successfully demonstrated the possibility of polymerizing via the 
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iniferter technique from a surface with the presence of AuNP previously attached on it. 
Moreover, the grafting of a MIP layer showed an effective imprinting, allowing the detection of 
TBZ in toluene that was not possible with the NIP. 
 
Figure 5.7 Comparison of SERS detection of TBZ using 1279 cm
-1
 peak with Si-Au-MIP and Si-
Au-NIP composite substrates: Additional medium intensity bands for TBZ can be found at 1452 
cm
-1
 and 1580 cm
-1
. The substrates were incubated with a 100 µM solution of thiabendazole in 
water. Spectra are offset for clarity.   
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CONCLUSION 
In summary, this work shows the feasibility of fabrication of a SERS-MIP substrate using 
iniferter living polymerization from the surface of a gold coated pre-formed particle. Further 
investigations will address optimal polymer grafting by adjusting the polymerization time. Also 
the binding capacity of the polymer, and the analytical performance of the SERS substrate will 
be completed for a more accurate determination of the detection power of the system. Future 
studies will also test this system in the presence of a mix of related pesticides to clearly 
demosntrate the specificity provided by this MIP-based sensor for final field applications.   
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Chapter 6: Teaching bioengineering and nano-technology in the middle school classroom 
environment. 
 
INTRODUCTION 
Use of the scientific method and inquiry based learning in the classroom is not often explored in 
secondary education.  To develop specialized instruction to employ this teaching style, a 
partnership was developed between a Cornell University graduate student and the 8th grade earth 
and physical science classes at Boyton Middle located locally in Ithaca, NY and taught by Mrs. 
Anne Gleed.  This collaboration was supported by the National Science Foundation funded GK-
12 program, which provides graduate students in the sciences the opportunity to communicate 
their research to grade school students.  Building these collaborative relationships is critical to 
inquiry based learning; working as a collaboration with the middle school teacher allowed for the 
teacher to use the resources of an collegiate laboratory 
284
.  The goal of the curriculum is to 
increase students’ exposure to research as it relates to nanotechnology and bioengineering.  For 
the curriculum guided inquiry based teaching technique was employed and four modules 
designed for inquiry based learning in a middle school classroom.   
 
The authors of the National Science Education Standards (NSES) define inquiry as a learning 
process in which the students are engaged in active learning, referring to inquiry as “something 
the students do, not something that is done to them” 285.  The NSES state that inquiry is central to 
learning science, allowing students to combine scientific knowledge with reasoning and thinking 
skills (p.2)
285.  The inquiry teaching method is based on the claim that “knowledge is built 
primarily from the learner’s experiences and interactions with phenomena”286.  With inquiry 
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based learning the student is a self-directed learner that processes information, makes 
observations, forms hypotheses, designs his or her own activities, and shares authority for their 
conclusions 
287, 288
.  As opposed to the traditional system where the student is a passive learner 
recording and memorizing given information, following directions, and deferring to the teacher 
as the authority 
287
.  As an active learner the student is able to think scientifically and view the 
world from a scientific perspective 
289
.   
The facilitator’s role is to develop opportunities and the framework in which students are able to 
generate appropriate conclusions and to guide the students as necessary 
286
.  The instructor must 
begin by introducing the students to a concrete concept,  followed by encouraging the students to 
make observation, raise questions, or make generalization from their observations 
286
.  
To accomplish this task, we have developed the module consisted with four components based 
on the 5-E learning model: Engage, Explore, Explain, Expand, and Evaluate/Assessment 
290
.  
The 5-E model is an instructional model, which allows the learner to build or construct new ideas 
using previous knowledge. The classroom curriculum included four modules designed with the 
following learning objectives: 
 Learn how researchers use latitude and longitude to track animals in the wild.  
 Investigate how a sneeze travels under different conditions.  
 Investigate what parts of a marine animal are the most contaminated with foreign 
microbes and how we use PCR to collect data.  
 Determine how to create a surface, which will allow gold nanoparticles to adhere to the 
surface to form substrates we can use for analytical detection.  
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The modules are designed to be taught over the course of the school year. Module 1 was 
conducted after the students studied latitude and longitude. The other modules were interspersed 
throughout the school year.  
 
MATERIALS 
Module 1 
Required Supplies: 
 Graph paper, Ruler, Pencil 
Module 2 
Required Supplies: 
 5-6 agar plates (For Each Pair), Over-night culture of B. subtilus in spray bottle , 
Ruler/meter stick, Masking tape, Marker, Diagram, Cleanser (0.2% bleach solution)  
Module 3 
Required Supplies: 
 Disposable inoculating loop, Swabs, Micropipette, Micropipette tips 
Module 4 
Required Supplies: 
 Microscope slides, Gold nanoparticle solution, (3-aminopropyl) triethoxysilane, 
Sodium dodecyl sulfate, Water, Micropipette, Micropipette tips   
METHODS 
Module 1: Sea Turtle  
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Engage (Time: 5-10min)  
Introduce the students to sea turtles and satellite telemetry. Explain how humans use tracking to 
map sea turtle movements to study the behavior of the animal. In an earth science class this 
lesson works well after students have completed the section on mapping. Have the students 
review latitude and longitude as a class and how to use tracking data to create a map.  
Explore (Time: 20-30min)  
Students pick a set of data they would like to map (Casey Key Loggerhead, Gulf of Mexico, 
winter) and choose the appropriate map. The students summarize the tracking data by choosing 
15 points from the data set. The summarized data set should be recorded on their worksheet in 
the following manner.  
Date Longitude Latitude 
7/9/2007 82.5 W 27.0 N 
7/10/2007 83.0 W 27.0 N 
 
The students can begin plotting their data on the map. They should begin to see a pattern 
develop. After the class has finished drawing their maps, collectively discuss the data. Have the 
groups come to the front of the class and describe how their animal was migrating during that 
time of year.  
Explain (Time: 10 min)  
The goal of this exercise is to show students that sea turtles, in particular females, have different 
migratory behavioral patterns depending on the time of year. The student should attempt to 
figure out whether the animal was nesting, resting, foraging, or migrating in their data set.  
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Expand (Time: Homework)  
The students can create more detailed maps using the seaturtle.org Maptool. This tool allows 
students to add data such as sea currents, coastlines, country names, and sea surface 
temperatures. They can also notice if there were any weather patterns that could have affects the 
migration pattern of the animal (i.e. Hurricane). Students can also adopt a sea turtle and track its 
movements online.  
 
Module 2: Sneeze Lab 
Engage (Time: 5-10min)  
This module is designed for students to determine how far a sneeze travels and if covering ones 
nose/mouth while sneezing has an effect on transmission. In addition they will learn how to 
identify and count bacterial colonies on an agar plate. The students will review basic concepts on 
microbes and scientific method terminology. Before the student design their experiment the 
teacher must discuss positive and negative controls. Let the class figure out how to make a 
positive control plate and a negative control plate. By the end of the lesson, students should have 
learned how to use the scientific method to test a hypothesis and how to work in groups to run an 
experiment.  
Explore (Time: 20-30min)  
1) The students (4-5) should set up their experiment by mapping out the locations of the agar 
plates with a measuring stick and marking the location with masking tape. The agar plates should 
be placed at specified locations on the work bench.  
2) Students should each record the experimental set up on the worksheet. They should label each 
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agar plates with the group name, date, and the position. If they are a group that is testing 
covering the nose, they should label the agar plates with the appropriate information.  
3) The students should remove each of the lids and place them next to the plates. I came to each 
group and sprayed the bottle allowing the mist to settle for a few seconds. The group can then 
replace the lids. If the group had a positive control I made the control by spraying the culture 
mist directly onto an empty plate.  
4) Use the bleach solution to clean the work area after spraying the bacteria.  
5) Let the plates incubate overnight and store at 4 ºC until next class period.  
6) During the next class period, students will count colonies on their plates. They should record 
the number of colonies on their worksheet and compare the results with the rest of the class. If 
their plate became a lawn of bacteria, I explained the difference between a lawn and single 
colonies. 
Explain (Time: 10 min)  
The students should learn how to make controls and run a simple experiment. They should 
understand how to make and test a hypothesis, making sure the different sets of data are 
comparable. Students should also learn how bacteria spread and grow. Students should be able to 
describe the scientific method by the end of the lesson.  
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Module 3: Marine Wildlife CSI 
Engage (Time: 10min)  
This module is designed to connect basic laboratory research with the activity of tracking sea 
turtles. In this activity student are tasked to be forensic pathologists and help animal doctors 
discover if bacterial pathogens are the cause of the animals in their hospital becoming ill. In the 
process of the discovery of microbiome of the diseased animals, student will learn the basics of 
polymerase chain reaction (PCR) and techniques for analyzing PCR products. Students will need 
to keep a detailed record of samples. Students will also learn how to use a micropipette and how 
to properly take a sample from a contaminated culture swab or specimen. At the conclusion of 
the lesson the student should demonstrate proficiency with several basic laboratory skills. In the 
process, students will discover the impact of human activity on the waters in the Gulf of Mexico 
as it relates to introduction of foreign pathogens into the Gulf ecosystem.  
Explore (Time: 20-30min)  
1. Sample preparation 
a. Students begin activity by putting a 20 μl aliquot of water into a PCR tube. The 
students should familiarize themselves with a micropipette and how to adjust the 
settings to the proper volume. Every student should get an opportunity to use the 
pipette so I had each student prepare at least one sample.  
2. Collection 
a. Once all tubes have been filled with the proper amount of liquid, the students can 
begin to sample. One student should be tasked with collecting a control from the 
room. The student should use the cleanroom swab to collect the sample 
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b. Another student can be charged with collecting biofilm from the specimen. Use the 
disposable inoculating loops to perform this task. I monitored this step so that 
students would be careful with the specimen.  
c. The inoculation loop should be dipped into the PCR tube. Close the microcentrifuge 
tube. 
 
Figure 6.1 Snapshots of student preparing reactions and taking specimen samples for PCR. 1A. 
Students begin by aliquoting 20 µL of sterile deionized water into a microcentrifuge tube. 2A. 
Using a sterile culture swab or inoculating loop, students collect a sample from a surface in the 
classroom or specimen (2B). 2C. Students inoculate microcentrifuge tube with sample.  
 
d. Student will then move to collecting samples from the swabs. Each group will be 
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given 4-5 swabs taken from various body parts (foot, armpit, urogenital) of a marine 
animal (manatee, dolphin, penguin, etc.). An extension of the exercise would be to 
give each student an anatomical diagram of the animal and have them label the 
location they are sampling.  
 
Figure 6.2 Snapshot of student taking samples from marine animal swabs for PCR identification 
of bacteria.   
 
3. Data Analysis (Day 1)  
a. In an effort to maximize class time I prepared a DNA agarose gel before class and ran 
samples I had previous collected. I explained how DNA travels through the gel and 
how we can visualize the DNA in the gel. Students took turns lighting up the gel 
under the dark reader.  
4. Data Analysis (Day 2)  
a. After the first class period, I added a ready-to-use PCR reaction mixture containing 
Taq polymerase to all of the samples and recorded the sample information. The PCR 
reactions were completed in the laboratory and I analyzed the samples by gel 
electrophoresis. The next class period we used for data analysis. The students were 
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shown which samples they collected were positive for bacteria.  
Explain (Time: 10 min)  
During the explanation student should understand how PCR can amplify DNA. I quizzed 
students on how many cycles it would take to produce billions of pieces of DNA. Students had to 
make connections to how some bacteria found in humans can infect an animal in the Gulf of 
Mexico.  
Expand (Time: Homework)  
Highly motivated students can learn more about 16S rDNA sequencing as a method of bacterial 
identification.  
 
Module 4: Nano-Engineers 
Engage (Time: 5-10min)  
This module is designed as an activity to show how we can use nanotechnology to create devices 
we can use for research. The goal is to teach students what nano-scale means and how we can 
manipulate objects on the nano-scale. Students are first introduced to an EM image of the growth 
of silicon nanowires from a gold surface that looked like a forest under false color. The student 
can make inferences on how small the objects were in the image. The activity also includes a 
short introduction to chemistry. The students need to understand that only certain molecules on 
the surface of their substrate can react with the chemical that will allow the gold to attach to the 
surface.  
Explore (Time: 45min)  
The goal of this activity is to allow the student as much freedom as possible to create the device. 
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The experiment can be conducted in one of two ways. The first way would be to use one 
chemical (APTES) and have the student vary the surface they use. In practice, a typical 
polystyrene surface does not react well with the APTES. This surface should not have as much 
gold attached as the glass surface treated with the APTES. The students can record the 
differences in the gold coating on the glass between the surfaces.  
Another possible lesson would be to introduce more variables into the system. For a more 
advanced class, I explained the surface chemistry principle and it was their responsibility to find 
the right chemical and surface that would give the most gold on the surface. They then had to 
identify the chemical and show why one would work over another. They also identified the 
control in the experiment.  
a) After picking a surface, students take a 50-100 μL aliquot of chemical solution and place 
it on the surface. Draw a circle around the drop with a marker. Allow the reaction to take 
place for at least 15 minutes.  
b) Thoroughly rinse off the surface with water. Dry the surface, careful not to touch the area 
inside the circle.  
c) Place a drop of gold inside the circle on the surface. Depending on the type of surface, 
the drop may spread outside of the circle. If this happens, reduce the volume of the gold 
solution added to the surface. Let the gold incubate on the surface for another 15 minutes. 
If time is limited the gold can incubate on the surface overnight. Keep the surface 
covered to limit evaporation.  
d) Rinse the gold from the surface and allow the plate to dry. The plates can be left to dry 
overnight and analyzed during the following class period.  
 136 
 
 
Figure 6.3 Snapshot of students preparing Surface Enhanced Raman substrates using gold 
nanoparticles chemically modified petri dishes. A. Students dispense 50-100 µL of APTES 
solution onto a glass microscope slide fitted into a small petri dish. B. The slide is rinsed after 10 
minutes of incubation. C. 50 µL of gold nanoparticle solution is placed on the rinsed microscope 
slide. D. The particles incubate on the surface for 15 minutes and excess particle solution is 
rinsed off.   
 
Explain (Time: 10 min)  
By the end of the lesson students should see the differences between the various substrates used 
in the experiment and if the chemical used reacted with the surface to allow the gold to bind. At 
the end of the experiment, students should be able to describe in general terms why some 
surfaces bind gold as others do not. They should also familiarize themselves with some basic 
chemistry principles.  
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Expand (Time: Homework)  
Highly motivated students can have their surface characterized using Scanning Electron 
Microscopy (SEM). An example of a gold coated glass surface created using the APTES reaction 
can be found in the appendix.  
 
RESULTS AND DISCUSSION 
Module 1: This module consists of student picking an animal to track, marking the animal’s 
location of a map, and connecting the mark to visualize the animal’s path. This activity requires 
some preparation by the teacher before the lesson. First the teacher must visit www.seaturtle.org 
and sign up for free access to tracking data for the classroom. Once access to the data has been 
granted, the teacher can choose data from several different species of sea turtle. The teacher must 
then identify what ocean the sea turtles are located in so they can download/print the appropriate 
tracking map also located on the website.  
Next, the teacher must divide the tracking data up by season (Spring-Winter). Some animals 
have more tracking data than others, so for this exercise it is important to choose several animals 
with large sets of data. Preparation time is approximately 3 hours.  
 
Module 2: This module will require the teacher to prepare or purchase as many as 30 LB agar 
plates. The number of agar plates can be decreased by altering the size of the work groups. The 
teacher will also need to prepare a spray bottle of nonpathogenic bacteria. The recommended cell 
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line for this experiment would be Bacillus subtilus. The teacher will also need to prepare a 
diagram showing to possible plate locations for the students to test.  
Module 3: This module requires preparation by the teacher to maximize the lesson time. The 
teacher will need to distribute and label all materials before the beginning of the lesson. The 
figure below shows an example of how to lay out the materials before the lesson. If the teacher is 
using specimens, it is recommended that the teacher distribute when the group is ready. If the 
teacher is going to show an agarose gel during the class, the gel must prepared and run before the 
class period. To prepare the gel dissolve 0.4 g of agarose into 50 ml of TAE buffer (Tris, acetate, 
EDTA) and add 0.5 μl of gel green dye of DNA visualization. Allow the gel to cool in a mold 
with comb. Run the gel at 100 V for 1 hour with pre-prepared samples. Store the gel in a sealed 
container until students are ready to see the gel. Due to the limited time, the PCR cannot be 
completed in one class period. The teacher should collect the samples and add the remaining 25 
μl of pre-mixed PCR reaction mixture to complete the PCR reaction. The teacher can then place 
the samples in a thermocycler to run overnight and analyze in the next class period. Lesson will 
take approximately 2 ½ class periods to complete.  
Module 4: This module requires some preparation by the teacher. The teacher must prepare all of 
the materials and reagents before the beginning of the activity. It is helpful to organize the 
materials similar to the layout below. The gold nanoparticles should be aliquoted into 
microcentrifuge tubes for each group. Also give each group an aliquot of each chemical. Be sure 
the students circle the drop they make on the surface so they can place the gold in the correct 
spot later on.  
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Assessment  
The following rubric can be used to assess students during each part of the activity. The term 
“expectations” here refers to the content, process and attitudinal goals for this activity. Evidence 
for understanding may be in the form of oral as well as written communication, both with the 
teacher as well as observed communication with other students. Specifics are listed in the table 
below.  
1= exceeds expectations  
2= meets expectations consistently  
3= meets expectations occasionally  
4= not meeting expectations  
Module Engage Explore Explain Expand/Synthesis 
1 
Student is eager to 
participate in group 
discussion. Offers help 
to his or her class mates 
during the discussion 
and uses prior 
knowledge develop a 
hypothesis for the 
lesson 
Student is highly 
engaged in the 
experiment and allowed 
others to participate in 
the lesson. They record 
their data correctly and 
required little assistance 
setting up experiment 
Student offers an 
insightful description 
the phenomena of the 
modules and develops a 
well thought out 
hypothesis. 
Student is an active 
participant in 
developing a conclusion 
to the lesson. They help 
their class mates 
understand the concepts 
discussed and ask for 
further examples. 
2 
Student participated in 
discussion 
Student was engaged in 
activity; they recorded 
their data, and 
completed the lab 
assignment. 
Student was an active 
participant in the class 
discussion 
Student developed 
proper conclusion to the 
lesson 
3 
Student only 
participated in 
discussion if asked 
Student was not highly 
engaged in the activity 
or did not allow others 
to participate. 
Assignments were 
incomplete. 
Student was a modest 
participant in 
discussion 
Student developed 
conclusion but not 
correct based on the 
results. 
4 
Student does not 
participate in the 
discussion and/or is a 
distraction to the rest of 
the group 
Student does not 
complete laboratory 
assignment and shows 
little interest in the 
activity 
Student does not 
participate or is a 
distraction during the 
discussion 
Student does not 
participate and did not 
reach a conclusion from 
the lesson 
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CHAPTER 7: CONCLUSIONS & FUTURE DIRECTIONS 
 
The work presented in this dissertation demonstrates the utility to molecularly imprinted 
polymers and aptamers use with surface enhanced Raman spectroscopy. The aptamer system 
provides a level of specificity to a SERS substrate that is not seen in most SERS based platforms. 
Furthermore there exists an extensive library of aptamer that bind small molecules and proteins 
which makes this system transferable to many fields. Molecularly imprinted polymers are 
potentially more attractive in that they are much more stable across a spectrum of conditions and 
the synthesis costs are a fraction of the cost of oligonucleotide synthesis.  
A potentially powerful drug delivery system was generated with molecular imprinting of 
doxorubicin. The common chemotherapy has a short serum half-life and is highly toxic. This 
molecularly imprinted polymer addresses these two factors in its specific trapping of the 
molecule within the polymer network which is resistance to enzymatic degradation. Future work 
will involve modifying the surface of the particles with a laser adsorption layer. The photo 
initiated heating of the polymer would cause a swelling of the matrix and result in burst release. 
The particles could then be conjugated with a targeting antibody and only a substantial release 
drug would occur when irradiated by a plasmon matching laser.   
Future work with CT antigens will involve development of Virus-Like Particles (VLP) decorated 
with the CT antigen NY-ESO-1 enhanced immunogenicity. Currently work is being conducted to 
modify norovirus P particle surface loops with either the MHC epitope of NY-ESO-1 or the full 
antigen and express the protein at the large scale in Pichia pastoris.  
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